<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Annals of Hematology via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Annals of Hematology' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Annals+of+Hematology&t=Annals+of+Hematology&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 17 Mar 2010 14:33:20 +0100</lastBuildDate>
        <item>
            <title>Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3371742&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F87100n1gr305243m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly
 diagnosed multiple myeloma (MM) patients older than 65&amp;nbsp;years or ineligible for transplant. The results of five phase III trials
 assessing thalidomide in combination with melphalan and prednisone (MPT) have demonstrated significantly improved response
 rates compared with melphalan and prednisone (MP) alone. Additionally, two of these studies showed that survival was extended
 by approximately 18&amp;nbsp;months in patients treated with MPT compared with MP alone. Thalidomide, in combination with MP, is associated
 with adverse events (AEs) including peripheral neuropathy and venous thromboembolism. In order to optimize the efficacy of
 MPT, a...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3371742</comments>
            <pubDate>Mon, 15 Mar 2010 17:54:34 +0100</pubDate>
            <guid isPermaLink="false">3371742</guid>        </item>
        <item>
            <title>Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series</title>
            <link>http://www.medworm.com/index.php?rid=3371743&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy566587n776n1772%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0932-2Authors
		Rita Coutinho, University of Barcelona Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic IDIBAPS Villarroel 170 08036 Barcelona SpainDolors Costa, University of Barcelona Hematopathology Unit, Hospital Clinic IDIBAPS Barcelona SpainAna Carrió, University of Barcelona Hematopathology Unit, Hospital Clinic IDIBAPS Barcelona SpainConcha Muñoz, University of Barcelona Hematopathology Unit, Hospital Clinic IDIBAPS Barcelona SpainAna Vidal, University of Barcelona Hematopathology Unit, Hospital Clinic IDIBAPS Barcelona SpainMohammed Belkaid, University of Barcelona Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic IDIBAPS Villarroel 170 0...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3371743</comments>
            <pubDate>Mon, 15 Mar 2010 17:54:33 +0100</pubDate>
            <guid isPermaLink="false">3371743</guid>        </item>
        <item>
            <title>Combining two orally active iron chelators for thalassemia</title>
            <link>http://www.medworm.com/index.php?rid=3360859&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc177745t6j34l3j4%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0933-1Authors
		Vasilios Berdoukas, The Children’s Hospital of Los Angeles The Division of Hematology/Oncology 4650 Sunset Blvd Los Angeles CA 90027-6016 USASusan Carson, The Children’s Hospital of Los Angeles The Division of Hematology/Oncology 4650 Sunset Blvd Los Angeles CA 90027-6016 USAAnne Nord, The Children’s Hospital of Los Angeles The Division of Hematology/Oncology 4650 Sunset Blvd Los Angeles CA 90027-6016 USAAni Dongelyan, The Children’s Hospital of Los Angeles The Division of Hematology/Oncology 4650 Sunset Blvd Los Angeles CA 90027-6016 USAStephen Gavin, The Children’s Hospital of Los Angeles The Division of Hematology/Oncology 4650 Sunset Blvd Los Angeles CA 90027-6016 USAThomas C. Ho...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360859</comments>
            <pubDate>Thu, 11 Mar 2010 02:38:47 +0100</pubDate>
            <guid isPermaLink="false">3360859</guid>        </item>
        <item>
            <title>Wnt and Notch signaling pathways selectively regulating hematopoiesis</title>
            <link>http://www.medworm.com/index.php?rid=3360861&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F30w5061655l02554%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hematopoietic stem and progenitor cells (HSPCs) are the source of all blood cells in the adult body. The pool of HSPCs is
 formed during embryogenesis process through a well-characterized succession of intra-embryonic regions and organs. The spatial
 and temporal restrictions in definitive hematopoietic development and the signaling molecules involved are of great interest
 as these may prove useful for generating and expanding these clinically important cell populations ex vivo. To elucidate the
 mechanism by which definitive HSPCs expand during this limited developmental time frame, we analyzed the spatial and temporal
 programmed gene expression patterns of Wnt and Notch signaling members during hematopoietic development. Genes related to
 the Wnt signaling pathway w...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360861</comments>
            <pubDate>Thu, 11 Mar 2010 02:38:46 +0100</pubDate>
            <guid isPermaLink="false">3360861</guid>        </item>
        <item>
            <title>MYH9-related disease: Report on five German families and description of a novel mutation</title>
            <link>http://www.medworm.com/index.php?rid=3360860&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbl057l8x4244353x%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0928-yAuthors
		Anna Savoia, University of Trieste Medical Genetics, Department of Reproductive and Developmental Sciences, Institute for Maternal and Child Health, IRCCS “Burlo Garofolo” Trieste ItalyManuela Germeshausen, Hannover Medical School Department of Pediatric Hematology and Oncology Hannover GermanyDaniela De Rocco, University of Trieste Medical Genetics, Department of Reproductive and Developmental Sciences, Institute for Maternal and Child Health, IRCCS “Burlo Garofolo” Trieste ItalyBettina Henschel, Marienhospital Gelsenkirchen Gelsenkirchen GermanyChristian P. Kratz, University of Freiburg Department of Pediatrics and Adolescent Medicine Freiburg GermanyMichaela Kuhlen, Center for Child...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360860</comments>
            <pubDate>Thu, 11 Mar 2010 02:38:46 +0100</pubDate>
            <guid isPermaLink="false">3360860</guid>        </item>
        <item>
            <title>Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP</title>
            <link>http://www.medworm.com/index.php?rid=3356148&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc8302372421wk0w7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Preclinical data indicated a detrimental effect of statins on the anti-lymphoma activity of rituximab. We evaluated the impact
 of concomitant statin medication on the response and survival of patients with diffuse large B cell lymphoma (DLBCL) receiving
 rituximab–cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) as first-line therapy. Medical histories of patients
 with DLBCL who were treated with R-CHOP as first-line therapy were assessed for concomitant statin use, response after completion
 of chemotherapy, event-free survival (EFS), and overall survival (OS). Furthermore, 2-[18F]fluor-2-deoxyglucose (FDG)-PET/CT results after completion of first-line therapy were compared between the groups. Overall,
 145 patients with DLBCL treated with R-CHOP fro...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3356148</comments>
            <pubDate>Wed, 10 Mar 2010 15:33:39 +0100</pubDate>
            <guid isPermaLink="false">3356148</guid>        </item>
        <item>
            <title>Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution</title>
            <link>http://www.medworm.com/index.php?rid=3356147&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl68x715r97764r44%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The present study was designed to establish the incidence of cytogenetic evolution (CE), defined as the acquisition of chromosomal
 defects during the course of MDS, in order to correlate it with the WHO classification and IPSS score, and to assess its impact
 on overall survival (OS) and risk of MDS/AML evolution (progression-free interval, PFI) by means of Cox models for time-dependent
 covariates. Adjustments for known risk factors were achieved by performing a bivariable analysis. The study was carried out
 in 153 MDS patients who were followed for a median period of 45.2&amp;nbsp;months. Disease progression occurred in 42.4% of patients
 after a 65.2-month median PFI, while CE occurred in 30.7% of patients. Our study shows that (1) CE was more common in advanced
 than ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3356147</comments>
            <pubDate>Wed, 10 Mar 2010 15:33:39 +0100</pubDate>
            <guid isPermaLink="false">3356147</guid>        </item>
        <item>
            <title>Gastric mucosa-associated lymphoid tissue lymphoma complicated with hemophagocytic syndrome in an elderly woman</title>
            <link>http://www.medworm.com/index.php?rid=3328713&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft1752l8600x72710%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0929-xAuthors
		Hitoshi Ohno, Takeda General Hospital Department of Hematology 28-1, Mori-minami-cho, Ishida, Fushimi-ku Kyoto 601-1495 JapanKengo Takimoto, Takeda General Hospital Department of Gastroenterology Kyoto Japan
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3328713</comments>
            <pubDate>Tue, 02 Mar 2010 10:00:21 +0100</pubDate>
            <guid isPermaLink="false">3328713</guid>        </item>
        <item>
            <title>Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies</title>
            <link>http://www.medworm.com/index.php?rid=3328712&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F365956137r144653%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite recent progress in molecular research in myeloid malignancies, in subsets of patients with myelodysplastic syndrome
 (MDS) so far no underlying mutation was identified. In the myeloproliferative neoplasms (MPNs), the JAK2V617F alone cannot explain the phenotypic heterogeneity. In acute myeloid leukemia (AML), clinical variability exists within
 distinct subgroups. Thus, the search for novel molecular markers continues. Recently, mutations of the tet oncogene family
 member 2 (TET2) and Casitas B-cell lymphoma (CBL) genes became the focus of interest. With diverse genetic methods, TET2 on chromosome 4q24 was identified as candidate tumor suppressor gene. Sequencing studies revealed heterogeneous mutations
 in 10–25% of patients with acute myeloid leukemia (AML)...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3328712</comments>
            <pubDate>Tue, 02 Mar 2010 10:00:21 +0100</pubDate>
            <guid isPermaLink="false">3328712</guid>        </item>
        <item>
            <title>Essential thrombocythemia as underlying cause of malabsorption syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3313072&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr6049hj127871113%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0924-2Authors
		Luciana Teofili, Catholic University Department of Hematology Rome ItalyLorenza Torti, Catholic University Department of Hematology Rome ItalyAlessandro Cina, Catholic University Department of Radiology Rome ItalyAntonio Gasbarrini, Catholic University Department of Internal Medicine Rome ItalyMarialuisa Novi, Catholic University Department of Internal Medicine Rome ItalyGiuseppe Leone, Catholic University Department of Hematology Rome ItalyLuigi Maria Larocca, Catholic University Department of Pathology Rome Italy
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3313072</comments>
            <pubDate>Thu, 25 Feb 2010 06:49:31 +0100</pubDate>
            <guid isPermaLink="false">3313072</guid>        </item>
        <item>
            <title>Mechanisms of platelet recovery in ITP associated with therapy</title>
            <link>http://www.medworm.com/index.php?rid=3308686&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F155m16q3445n7077%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Immune thrombocytopenia (ITP) is an autoimmune disease primarily characterized by increased clearance of auto-antibody-sensitized
 platelets by Fc-receptor-bearing macrophages in the spleen and liver. It has been classically accepted that antibody-mediated
 platelet destruction is Fc dependent. Recent studies, however, may also indicate the involvement of Fc-independent pathways
 of platelet destruction. Current treatment options work by immunosuppression (e.g., corticosteroids), immunomodulation (e.g.,
 IVIg and anti-D), or removal of the platelet destruction site (splenectomy) in ITP. This review will discuss the mechanisms
 of action of these and other treatments for ITP.
 
 
	Content Type Journal ArticleCategory Basic ScienceDOI 10.1007/s00277-010-0916-2Authors
		So...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308686</comments>
            <pubDate>Wed, 24 Feb 2010 06:47:48 +0100</pubDate>
            <guid isPermaLink="false">3308686</guid>        </item>
        <item>
            <title>Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes</title>
            <link>http://www.medworm.com/index.php?rid=3308687&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F87138km2x72g0643%2F</link>
            <description>In this study, we evaluated the prognostic
 value of International Prognostic Scoring System (IPSS) and World Health Organization classification-based prognostic scoring
 system (WPSS) in 164 adult MDS patients with abnormal karyotypes. We also analyzed the prognostic relevance of mean corpuscular
 volume (MCV) in these patients. We found that both IPSS and WPSS had strong prognostic value in patients with abnormal karyotypes
 (P &amp;lt; 0.001, P &amp;lt; 0.001). Furthermore, we observed the significant differences in the survival of patients with abnormal karyotypes based
 on MCV stratification: The median survival of patients with macrocytosis was 31.0&amp;nbsp;months, significantly longer than the 16.5-month
 median survival time of patients with MCVs of less than 100&amp;nbsp;fl (P = 0.00...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308687</comments>
            <pubDate>Wed, 24 Feb 2010 06:47:47 +0100</pubDate>
            <guid isPermaLink="false">3308687</guid>        </item>
        <item>
            <title>Hematologic malignancy as a risk factor for bacteremic skin and soft tissue infection caused by gram-negative bacilli</title>
            <link>http://www.medworm.com/index.php?rid=3308689&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F72287h3136j012v1%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0914-4Authors
		Cheol-In Kang, Sungkyunkwan University School of Medicine Division of Infectious Diseases, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 Republic of KoreaDoo Ryeon Chung, Sungkyunkwan University School of Medicine Division of Infectious Diseases, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 Republic of KoreaKyong Ran Peck, Sungkyunkwan University School of Medicine Division of Infectious Diseases, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 Republic of KoreaJae-Hoon Song, Sungkyunkwan University School of Medicine Division of Infectious Diseases, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 Republic of KoreaKorean Network ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308689</comments>
            <pubDate>Wed, 24 Feb 2010 06:47:46 +0100</pubDate>
            <guid isPermaLink="false">3308689</guid>        </item>
        <item>
            <title>Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib</title>
            <link>http://www.medworm.com/index.php?rid=3308688&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp1624724025u6473%2F</link>
            <description>In conclusion,
 escalated dose imatinib shows considerable efficacy with tolerable toxicity in CML patients showing suboptimal response to
 standard dose imatinib. EMR is an early predictive marker for positive imatinib response.
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-010-0910-8Authors
		Youngil Koh, Seoul National University Hospital Department of Internal Medicine 28 Yongon-dong, Jongno-gu Seoul 110-744 Republic of KoreaInho Kim, Seoul National University Hospital Department of Internal Medicine 28 Yongon-dong, Jongno-gu Seoul 110-744 Republic of KoreaSung-Soo Yoon, Seoul National University Hospital Department of Internal Medicine 28 Yongon-dong, Jongno-gu Seoul 110-744 Republic of KoreaByoung Kook Kim, Seoul National University Hospital Department ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308688</comments>
            <pubDate>Wed, 24 Feb 2010 06:47:46 +0100</pubDate>
            <guid isPermaLink="false">3308688</guid>        </item>
        <item>
            <title>The role of Fcγ receptors in murine autoimmune thrombocytopenia</title>
            <link>http://www.medworm.com/index.php?rid=3308690&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6g54380450767358%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Immune thrombocytopenia (ITP) can become a life-threatening condition that requires immediate medical attention. The loss
 in platelet numbers during ITP can be induced by a variety of triggers. Anti-platelet antibodies of several isotypes and subclasses
 are a major cause for ITP and are a hallmark of many complex autoimmune diseases such as systemic lupus erythematosus. Mouse
 models have been important to understand the effector pathways involved in antibody-mediated platelet depletion. Therapeutic
 interventions based on these results have been proven successful in treating human ITP, thus validating the use of these model
 systems. One major problem that remains to be answered is which cell populations are crucial for platelet removal. Targeting
 these cells direct...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308690</comments>
            <pubDate>Wed, 24 Feb 2010 06:47:45 +0100</pubDate>
            <guid isPermaLink="false">3308690</guid>        </item>
        <item>
            <title>Acute lymphoblastic leukemia masquerading as juvenile rheumatoid arthritis: no association with survival</title>
            <link>http://www.medworm.com/index.php?rid=3304251&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb72nq10609p28gwk%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0922-4Authors
		Matthew J. Murray, Department of Paediatric Haematology and Oncology, Addenbrooke’s Hospital Cambridge CB2 0QQ UKMichael Gattens, Department of Paediatric Haematology and Oncology, Addenbrooke’s Hospital Cambridge CB2 0QQ UKJames C. Nicholson, Department of Paediatric Haematology and Oncology, Addenbrooke’s Hospital Cambridge CB2 0QQ UK
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3304251</comments>
            <pubDate>Tue, 23 Feb 2010 07:19:00 +0100</pubDate>
            <guid isPermaLink="false">3304251</guid>        </item>
        <item>
            <title>Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors</title>
            <link>http://www.medworm.com/index.php?rid=3304253&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Far218280721g3h4v%2F</link>
            <description>In conclusion, the survival and relapse incidence were not significantly different between the related and
 unrelated PBSCT.
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-010-0913-5Authors
		Byung Woog Kang, Kyungpook National University Hospital, Kyungpook National University School of Medicine Department of Hematology/Oncology 200 Dongduk-Ro, Jung-Gu Daegu 700-712 South KoreaJoon Ho Moon, Kyungpook National University Hospital, Kyungpook National University School of Medicine Department of Hematology/Oncology 200 Dongduk-Ro, Jung-Gu Daegu 700-712 South KoreaYee Soo Chae, Kyungpook National University Hospital, Kyungpook National University School of Medicine Department of Hematology/Oncology 200 Dongduk-Ro, Jung-Gu Daegu 700-712 South KoreaJong Gwang Kim, K...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3304253</comments>
            <pubDate>Tue, 23 Feb 2010 07:18:59 +0100</pubDate>
            <guid isPermaLink="false">3304253</guid>        </item>
        <item>
            <title>Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors</title>
            <link>http://www.medworm.com/index.php?rid=3304252&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3747m85808237416%2F</link>
            <description>In this report we studied the
 various angiogenesis parameters like microvessel density (MVD) and total vascular area (TVA), on bone marrow biopsies in 50
 newly diagnosed cases of MM. The aim was to study bone marrow angiogenesis in MM using light microscopy (MVD-A) and computerized
 image analyzer (MVD-B and TVA) and correlate it with clinical features, laboratory findings, histological features, and response
 to treatment on follow-up. Bone marrow biopsies of test cases (n = 50) were immunohistochemically stained with CD34 for visualization of microvessels. MVD-A (range 8–80; mean 50.4; SD 17.5),
 MVD-B (5.2–33.2; mean 16.3; SD 5.1), and TVA in percentage (range 0.42–7.20; mean 2.8; SD 1.5) were measured. Ten age- and
 sex-matched controls were studied and their parameters wer...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3304252</comments>
            <pubDate>Tue, 23 Feb 2010 07:18:59 +0100</pubDate>
            <guid isPermaLink="false">3304252</guid>        </item>
        <item>
            <title>Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline</title>
            <link>http://www.medworm.com/index.php?rid=3296085&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F854051l2422x7302%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0911-7Authors
		Herwig Pieringer, General Hospital Linz 2nd Department of Medicine, Section of Nephrology Krankenhausstr. 9 Linz 4020 AustriaBernhard Schmekal, General Hospital Linz 2nd Department of Medicine, Section of Nephrology Krankenhausstr. 9 Linz 4020 AustriaGeorg Biesenbach, General Hospital Linz 2nd Department of Medicine, Section of Nephrology Krankenhausstr. 9 Linz 4020 AustriaErich Pohanka, General Hospital Linz 2nd Department of Medicine, Section of Nephrology Krankenhausstr. 9 Linz 4020 Austria
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3296085</comments>
            <pubDate>Sat, 20 Feb 2010 06:49:01 +0100</pubDate>
            <guid isPermaLink="false">3296085</guid>        </item>
        <item>
            <title>Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?</title>
            <link>http://www.medworm.com/index.php?rid=3285474&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu2hk601367330005%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A sequential treatment approach is the rule in CML and Ph+ ALL with imatinib failure being followed by second-line tyrosine kinase inhibitors. The sequential strategy may be vulnerable
 to compound mutations. An alternative and fascinating hypothesis discussed in this paper is the upfront use, at least in very
 high-risk Ph+ leukemias, of ABL kinase inhibitor combinations, either simultaneously or sequentially to target a wider range of mutations-based
 drug resistance. The main questions are: will TKI cocktails be able to eliminate the leukemic compartment? Which are the correct
 doses? Which are the long-term effects? Clinical trials have been recently initiated, and the future will give us the answer
 to all these questions.
 
 
	Content Type Journal ArticleCategory ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285474</comments>
            <pubDate>Wed, 17 Feb 2010 18:27:29 +0100</pubDate>
            <guid isPermaLink="false">3285474</guid>        </item>
        <item>
            <title>Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects</title>
            <link>http://www.medworm.com/index.php?rid=3274020&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F086u34473u3427j1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Romiplostim is an Fc-peptide fusion protein that activates intracellular transcriptional pathways via the thrombopoietin (TPO)
 receptor leading to increased platelet production. Romiplostim has been engineered to have no amino acid sequence homology
 to endogenous TPO. Recombinant protein therapeutics can be at a risk of development of an antibody response that can impact
 efficacy and safety. Hence, a strategy to detect potential antibody formation to the drug and to related endogenous molecules
 can be useful. The immunogenicity assessment strategy involved both the detection and characterization of binding and neutralizing
 antibodies. The method for detection was based on a surface plasmon resonance biosensor platform using the Biacore 3000. Samples
 that tested po...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3274020</comments>
            <pubDate>Sat, 13 Feb 2010 06:45:56 +0100</pubDate>
            <guid isPermaLink="false">3274020</guid>        </item>
        <item>
            <title>Traumatic subcapsular splenic hematoma revealing littoral cell angioma and Gaucher’s disease</title>
            <link>http://www.medworm.com/index.php?rid=3274021&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F725542534q126g6g%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0909-1Authors
		Fabien Forest, Centre Hospitalier Universitaire de Saint-Etienne Department of Pathology Saint-Etienne FranceSébastien Duband, Centre Hospitalier Universitaire de Saint-Etienne Department of Pathology Saint-Etienne FranceAlix Clemenson, Centre Hospitalier Universitaire de Saint-Etienne Department of Pathology Saint-Etienne FranceMichel Peoc’h, Centre Hospitalier Universitaire Service d’Anatomie pathologique Hôpital Bellevue 420055 Saint-Etienne Cedex 02 France
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3274021</comments>
            <pubDate>Sat, 13 Feb 2010 06:45:55 +0100</pubDate>
            <guid isPermaLink="false">3274021</guid>        </item>
        <item>
            <title>A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs</title>
            <link>http://www.medworm.com/index.php?rid=3264393&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2411ww1152148518%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still undetermined. In particular,
 the recommended target of hematocrit (Hct) &amp;lt;0.45 has been recently questioned and alkylating drugs are still used for elderly
 patients. We revised, according to WHO criteria, 300 PV diagnosis and evaluated the impact on clinical outcome of median Hct
 and of the strategy to administer anti-thrombotic prophylaxis and to avoid alkylating chemotherapy in almost all patients.
 Of 226 patients with WHO-confirmed diagnosis (median age 66), 91.3% survived at the median follow-up of 5.84&amp;nbsp;years and 77.5%
 are projected alive at 13&amp;nbsp;years. Eighteen percent had major thrombosis and 2.7% acute myeloid leukemia. Twenty-two percent
 of patients maint...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3264393</comments>
            <pubDate>Tue, 09 Feb 2010 17:35:20 +0100</pubDate>
            <guid isPermaLink="false">3264393</guid>        </item>
        <item>
            <title>Coexistence of thyroid metastasis carcinoma in the background of HT and primary thyroid mucosa-associated lymphoid tissue B cell lymphoma in a thyroid gland</title>
            <link>http://www.medworm.com/index.php?rid=3264394&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq946078614686220%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0906-4Authors
		Bin Li, Xiangya Hospital, Central South University Division of Oncology Xiangya Road 87# Changsha Hunan 410008 People’s Republic of ChinaYouhong Tang, Xiangya Hospital, Central South University Division of Oncology Xiangya Road 87# Changsha Hunan 410008 People’s Republic of ChinaDesheng Xiao, Xiangya Hospital, Central South University Division of Pathology Xiangya Road 87# Changsha Hunan 410008 People’s Republic of ChinaMeizuo Zhong, Xiangya Hospital, Central South University Division of Oncology Xiangya Road 87# Changsha Hunan 410008 People’s Republic of China
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3264394</comments>
            <pubDate>Mon, 08 Feb 2010 17:28:18 +0100</pubDate>
            <guid isPermaLink="false">3264394</guid>        </item>
        <item>
            <title>Human promoter mutations unveil Oct-1 and GATA-1 opposite action on Gfi1b regulation</title>
            <link>http://www.medworm.com/index.php?rid=3264395&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy7h17815j3j201q5%2F</link>
            <description>This study provides evidences of a new mechanism for Gfi1b repression. This is also the first report of Gfi1b mutations with
 a functional implication; further investigation and follow-up will clarify the involvement of these mutations in hematological
 disease.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0900-xAuthors
		Aurora Hernández, University Complutense Hematology Department, Hospital Clinico San Carlos 28040 Madrid SpainAna Villegas, University Complutense Hematology Department, Hospital Clinico San Carlos 28040 Madrid SpainEduardo Anguita, University Complutense Hematology Department, Hospital Clinico San Carlos 28040 Madrid Spain
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3264395</comments>
            <pubDate>Mon, 08 Feb 2010 17:28:17 +0100</pubDate>
            <guid isPermaLink="false">3264395</guid>        </item>
        <item>
            <title>Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=3241381&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F55761345x113p5pp%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The data about the fatty acid (FA) status of non-Hodgkin lymphoma (NHL) patients are poor. Therefore, the aim of this study
 was to investigate the FA profile of serum phospholipids in NHL patients related to the aggressiveness and clinical stage
 of NHL. We analyzed the FA profile of serum phospholipids in 47 newly diagnosed, untreated NHL patients and in 29 healthy
 subjects. Significantly higher (p &amp;lt; 0.001) levels of palmitic (16:0), oleic (18:1 n-9) and arachidonic acids (20:4 n-6), saturated and monounsaturated FA were
 found in NHL patients, while linoleic acid (18:2 n-6) and the levels of total polyunsaturated FA (PUFA), n-3 PUFA, eicosapentaenoic
 (20:5 n-3) and docosahexaenoic (DHA, 22:6 n-3) were significantly reduced (p &amp;lt; 0.01). The level of ole...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3241381</comments>
            <pubDate>Tue, 02 Feb 2010 17:46:52 +0100</pubDate>
            <guid isPermaLink="false">3241381</guid>        </item>
        <item>
            <title>Hyperlipidemic myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3233252&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk6qh7q926q560468%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0905-5Authors
		Alessandro Gozzetti, University of Siena Division of Hematology and Transplants, Policlinico “Santa Maria alle Scotte” Viale Bracci 16 53100 Siena ItalyMarzia Defina, University of Siena Division of Hematology and Transplants, Policlinico “Santa Maria alle Scotte” Viale Bracci 16 53100 Siena ItalyMonica Bocchia, University of Siena Division of Hematology and Transplants, Policlinico “Santa Maria alle Scotte” Viale Bracci 16 53100 Siena ItalyFrancesco Lauria, University of Siena Division of Hematology and Transplants, Policlinico “Santa Maria alle Scotte” Viale Bracci 16 53100 Siena Italy
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annal...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3233252</comments>
            <pubDate>Mon, 01 Feb 2010 18:02:13 +0100</pubDate>
            <guid isPermaLink="false">3233252</guid>        </item>
        <item>
            <title>Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report</title>
            <link>http://www.medworm.com/index.php?rid=3233251&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu0l1881nj85k8264%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0903-7Authors
		Stefano Sansone, Central Hospital of Bolzano Division of Internal Medicine Lorenz-Böhler Street 5 39100 Bolzano ItalyJohanna Rottensteiner, Central Hospital of Bolzano Division of Internal Medicine Lorenz-Böhler Street 5 39100 Bolzano ItalyJudith Stocker, Central Hospital of Bolzano Division of Oncology Lorenz-Böhler Street 5 39100 Bolzano ItalyCarlo Rosanelli, Central Hospital of Bolzano Division of Hematology and Bone Marrow Transplantation Lorenz-Böhler Street 5 39100 Bolzano ItalyChristian Josef Wiedermann, Central Hospital of Bolzano Division of Internal Medicine Lorenz-Böhler Street 5 39100 Bolzano Italy
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (S...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3233251</comments>
            <pubDate>Mon, 01 Feb 2010 18:02:13 +0100</pubDate>
            <guid isPermaLink="false">3233251</guid>        </item>
        <item>
            <title>Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells</title>
            <link>http://www.medworm.com/index.php?rid=3233253&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F23513g747211n816%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Treatment of acute myeloid leukemia (AML) remains challenging with many patients harboring unfavorable prognostic parameters
 such as FLT3 internal tandem duplication (FLT3-ITD) mutations leading to a constitutively activated FLT3-receptor tyrosine kinase (RTK). Activation of proteins by phosphorylation
 of tyrosine residues is a common mechanism in leukemia development. Therefore, specific tyrosine kinase inhibitors (TKI) have
 been developed for AML therapy and are currently under investigation. The staurosporine derivate PKC412 (Midostaurin) was
 found to be an effective inhibitor of the FLT3-RTK and is currently undergoing clinical trials for FLT3-mutated AML patients. Since resistance towards TKIs has been observed in vitro and in clinical trials, we have generated...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3233253</comments>
            <pubDate>Mon, 01 Feb 2010 06:45:51 +0100</pubDate>
            <guid isPermaLink="false">3233253</guid>        </item>
        <item>
            <title>Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy</title>
            <link>http://www.medworm.com/index.php?rid=3229136&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp3586n8464126743%2F</link>
            <description>This study demonstrates a significant reduction in MSC expansion and MSC CD44 expression by MSCs
 derived from patients receiving HDC regimens, thus implicating potential disadvantages in the use of autologous MSCs in chemotherapeutically
 pretreated patients for future therapeutic strategies. The clinical importance of these HDC-induced defects we have observed
 could be determined through prospective randomized trials of the effects of MSC cotransplantation on hematopoietic recovery
 in the setting of HDC with and without hematopoietic stem cell rescue.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0896-2Authors
		Kevin Kemp, University of the West of England Center for Research in Biomedicine, Faculty of Applied Sciences Bristol UKRuth Morse, University ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3229136</comments>
            <pubDate>Fri, 29 Jan 2010 17:57:51 +0100</pubDate>
            <guid isPermaLink="false">3229136</guid>        </item>
        <item>
            <title>Serological response to influenza vaccine after hematopoetic stem cell transplantation</title>
            <link>http://www.medworm.com/index.php?rid=3229135&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy50u0rk14m073803%2F</link>
            <description>In conclusion, the patients should be vaccinated as early as possible in the influenza season, before
 they are exposed to the virus.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0897-1Authors
		S. Songül Yalçın, Hacettepe University Unit of Social Pediatrics, Department of Pediatrics, Faculty of Medicine 06100 Ankara TurkeyMeda Kondolot, Hacettepe University Unit of Social Pediatrics, Department of Pediatrics, Faculty of Medicine 06100 Ankara TurkeyNurhan Albayrak, Virology Unit of Refik Saydam Hıfzıssıha Center Ankara TurkeyA. Başak Altaş, Virology Unit of Refik Saydam Hıfzıssıha Center Ankara TurkeyYasemin Karacan, Hacettepe University Unit of Hematopoetic Stem Cell Transplantation, Department of Internal Medicine, Faculty of Medicine Ankara ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3229135</comments>
            <pubDate>Fri, 29 Jan 2010 17:57:51 +0100</pubDate>
            <guid isPermaLink="false">3229135</guid>        </item>
        <item>
            <title>Areas with high soil percolation by herbicides have higher incidence of low-grade non-Hodgkin lymphomas</title>
            <link>http://www.medworm.com/index.php?rid=3224062&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh81748470242p0t2%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0898-0Authors
		Rita Fazzi, University of Pisa Division of Hematology, Department of Oncology, Transplants and Advances in Medicine Pisa ItalyChiara Manetti, Division of Oncology, Azienda Ospedaliera Lucca Lucca ItalyDaniele Focosi, University of Pisa Division of Hematology, Department of Oncology, Transplants and Advances in Medicine Pisa ItalyLucia Miligi, Environmental and Occupational Epidemiology Institute for Study and Cancer Prevention, ISPO Florence ItalyAlessandra Benvenuti, Environmental and Occupational Epidemiology Institute for Study and Cancer Prevention, ISPO Florence ItalyEnrico Bonari, Scuola Superiore di Studi Universitari e Perfezionamento Sant’Anna Pisa ItalyRoberto Barale, University of...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224062</comments>
            <pubDate>Thu, 28 Jan 2010 17:59:35 +0100</pubDate>
            <guid isPermaLink="false">3224062</guid>        </item>
        <item>
            <title>Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain</title>
            <link>http://www.medworm.com/index.php?rid=3224063&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3g7858087884t624%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mutations in the HFE gene result in iron overload and can produce hereditary hemochromatosis (HH), a disorder of iron metabolism
 characterized by increased intestinal iron absorption. Dietary quality, alcoholism and other life-style factors can increase
 the risk of iron overload, especially among genetically at risk populations. Polymorphisms of the HFE gene (C282Y, H63D and
 S65C) were measured together with serum ferritin (SF), transferrin saturation (TS) and hemoglobin, to measure iron status,
 in randomly-selected healthy subjects living in the Spanish Mediterranean coast (n = 815; 425 females, 390 males), 18 to 75&amp;nbsp;years of age. The intake of dietary components that affect iron absorption was calculated
 from 3-day dietary records. The presence of C282Y/H...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224063</comments>
            <pubDate>Wed, 27 Jan 2010 20:24:47 +0100</pubDate>
            <guid isPermaLink="false">3224063</guid>        </item>
        <item>
            <title>Two case reports of non-secretary-Ig types of lymphoplasmacytic lymphoma (LPL)</title>
            <link>http://www.medworm.com/index.php?rid=3224064&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft3158514q5567238%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-010-0902-8Authors
		Kichinosuke Kobayashi, Osaka Medical College Department of Internal Medicine (I) 2-7 Daigakumachi Takatsuki Osaka 569-0801 JapanTaiji Yokote, Osaka Medical College Department of Internal Medicine (I) 2-7 Daigakumachi Takatsuki Osaka 569-0801 JapanYuji Hirata, Osaka Medical College Department of Internal Medicine (I) 2-7 Daigakumachi Takatsuki Osaka 569-0801 JapanShoko Nakayama, Osaka Medical College Department of Internal Medicine (I) 2-7 Daigakumachi Takatsuki Osaka 569-0801 JapanNobuya Hiraoka, Osaka Medical College Department of Internal Medicine (I) 2-7 Daigakumachi Takatsuki Osaka 569-0801 JapanAyami Takayama, Osaka Medical College Department of Internal Medicine (I) 2-7 Daigakumachi Taka...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224064</comments>
            <pubDate>Wed, 27 Jan 2010 20:24:46 +0100</pubDate>
            <guid isPermaLink="false">3224064</guid>        </item>
        <item>
            <title>Increased osteoclastic activity as shown by increased sRANK-L/OPG ratio in boys with hemophilia</title>
            <link>http://www.medworm.com/index.php?rid=3190978&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx774142g70711706%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0894-4Authors
		Athanasios Christoforidis, Aristotle University of Thessaloniki First Paediatric Department 59, Konstantinoupoleos Str 54642 Thessaloniki GreeceMarina Economou, Aristotle University of Thessaloniki First Paediatric Department 59, Konstantinoupoleos Str 54642 Thessaloniki GreeceEvangelia Farmaki, Aristotle University of Thessaloniki First Paediatric Department 59, Konstantinoupoleos Str 54642 Thessaloniki GreeceVasiliki Tzimouli, Aristotle University of Thessaloniki First Paediatric Department 59, Konstantinoupoleos Str 54642 Thessaloniki GreeceNikos Gombakis, Aristotle University of Thessaloniki First Paediatric Department 59, Konstantinoupoleos Str 54642 Thessaloniki GreeceMiranda Athanassiou...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190978</comments>
            <pubDate>Mon, 18 Jan 2010 18:44:18 +0100</pubDate>
            <guid isPermaLink="false">3190978</guid>        </item>
        <item>
            <title>T-cell large granular lymphocyte leukemia: an Asian perspective</title>
            <link>http://www.medworm.com/index.php?rid=3190979&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnn35537m03px2m2l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To characterize T-cell large granular leukemia in Asia, 22 Chinese patients from a single institute were reported, together
 with an analysis of 88 Asian and 272 Western patients identified from the literature. In our cohort, anemia due to pure red
 cell aplasia (PRCA) occurred in 15/22 (68%) of cases, being the most common indication for treatment. Neutropenia was only
 found in 8/22 (36%) cases, and recurrent infections, the most important clinical problem in Western patients, were not observed.
 None of our cases presented with rheumatoid arthritis. These clinical features were consistently observed when compared with
 the 88 other Asian patients. Combined data from our cohort and other Asian cases showed that Asian patients, compared with
 Western patients, had more...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190979</comments>
            <pubDate>Mon, 18 Jan 2010 18:44:17 +0100</pubDate>
            <guid isPermaLink="false">3190979</guid>        </item>
        <item>
            <title>Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia</title>
            <link>http://www.medworm.com/index.php?rid=3190980&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe14061q5t562r015%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The pathogenesis of severe aplastic anemia (SAA) has not been completely understood, and insufficiency of the hematopoietic
 microenvironment can be an important factor. Here, we compared the basic properties of mesenchymal stem cells (MSCs), a major
 component of bone marrow microenvironment, from five SAA children with those of MSCs from five controls. Although MSCs from
 SAA children and controls were similar in morphology and immunophenotypic profile, SAA MSCs had slower expansion rate and
 smaller cumulative population doubling (1.83 ± 1.21 vs 3.36 ± 0.87; p = 0.046), indicating lower proliferative capacity. After osteogenic induction, SAA MSCs showed lower alkaline phosphatase
 activity (optical density, 1.46 ± 0.04 vs 2.27 ± 0.32; p = ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190980</comments>
            <pubDate>Mon, 18 Jan 2010 18:44:16 +0100</pubDate>
            <guid isPermaLink="false">3190980</guid>        </item>
        <item>
            <title>Pancytopenia and severe sepsis in an adult case of congenital X-linked agammaglobulinemia (XLA)</title>
            <link>http://www.medworm.com/index.php?rid=3190981&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl750t46242l0q324%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0891-7Authors
		Andrea Tendas, Sant’Eugenio Hospital Hematology Unit Rome ItalyPasquale Niscola, Sant’Eugenio Hospital Hematology Unit Rome ItalyTeresa Dentamaro, Sant’Eugenio Hospital Hematology Unit Rome ItalyLuca Cupelli, Sant’Eugenio Hospital Hematology Unit Rome ItalyGigliola Di Matteo, Tor Vergata University Department of Public Health Rome ItalyAndrea Finocchi, Tor Vergata University Department of Public Health Rome ItalyAgostina Siniscalchi, Sant’Eugenio Hospital Hematology Unit Rome ItalyStefano Fratoni, Sant’Eugenio Hospital Pathology Department Rome ItalyTeresa Scimò, Sant’Eugenio Hospital Hematology Unit Rome ItalyLaura Scaramucci, Sant’Eugenio Hospital Hematology Unit Rome ItalyM...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190981</comments>
            <pubDate>Fri, 15 Jan 2010 00:41:40 +0100</pubDate>
            <guid isPermaLink="false">3190981</guid>        </item>
        <item>
            <title>Protein C (PROC) gene mutations in two Indian families with purpura fulminans</title>
            <link>http://www.medworm.com/index.php?rid=3190982&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F48n7150560v2125v%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0893-5Authors
		Navin Pai, National Institute of Immunohaematology (ICMR) Department of Haemostasis and Thrombosis 13th Floor, KEM Hospital, Parel Mumbai 400 012 IndiaShrimati Shetty, National Institute of Immunohaematology (ICMR) Department of Haemostasis and Thrombosis 13th Floor, KEM Hospital, Parel Mumbai 400 012 IndiaKanjaksha Ghosh, National Institute of Immunohaematology (ICMR) Department of Haemostasis and Thrombosis 13th Floor, KEM Hospital, Parel Mumbai 400 012 India
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190982</comments>
            <pubDate>Fri, 15 Jan 2010 00:41:39 +0100</pubDate>
            <guid isPermaLink="false">3190982</guid>        </item>
        <item>
            <title>Pneumocystis jiroveci pneumonia detected by FDG-PET</title>
            <link>http://www.medworm.com/index.php?rid=3169145&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fvx128630v7718613%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0888-2Authors
		Tomonori Nakazato, Yokohama Municipal Citizen’s Hospital Department of Hematology 56 Okazawa-cho, Hodogaya-ku Yokohama 240-8555 JapanAi Mihara, Yokohama Municipal Citizen’s Hospital Department of Hematology 56 Okazawa-cho, Hodogaya-ku Yokohama 240-8555 JapanYukinari Sanada, Yokohama Municipal Citizen’s Hospital Department of Hematology 56 Okazawa-cho, Hodogaya-ku Yokohama 240-8555 JapanKazuhito Suzuki, Yokohama Municipal Citizen’s Hospital Department of Hematology 56 Okazawa-cho, Hodogaya-ku Yokohama 240-8555 JapanYoshinobu Aisa, Yokohama Municipal Citizen’s Hospital Department of Hematology 56 Okazawa-cho, Hodogaya-ku Yokohama 240-8555 JapanMichio Iwabuchi, Yokohama Municipal Citize...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3169145</comments>
            <pubDate>Mon, 11 Jan 2010 18:19:40 +0100</pubDate>
            <guid isPermaLink="false">3169145</guid>        </item>
        <item>
            <title>Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=3169146&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcm74534458478507%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mutations of the Fms-like tyrosine kinase 3 (FLT3) can be detected in a significant number of acute myeloid leukemias (AML). Seventy-five cases of acute myeloid leukemia were
 evaluated for FLT3-internal tandem duplications (ITD) by polymerase chain reaction. Paraffin-embedded formalin-fixed trephine biopsies of these
 cases were evaluated for expression of phosphorylated signal transducer and activator of transcription 1 (pSTAT1), pSTAT3,
 and pSTAT5. Specific expression of pSTAT5 was proven in leukemic blasts in situ by double staining with a blast-specific marker.
 Expression of pSTAT5 in ≥1% of blasts was highly predictive of FLT3-ITD. Neither expression of pSTAT1 nor pSTAT3 were associated with FLT3 mutations. Altogether we conclude that pSTAT5 expression can pre...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3169146</comments>
            <pubDate>Mon, 11 Jan 2010 18:19:39 +0100</pubDate>
            <guid isPermaLink="false">3169146</guid>        </item>
        <item>
            <title>Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML</title>
            <link>http://www.medworm.com/index.php?rid=3154645&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F35h257423w667807%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Angiogenesis plays an important role in the growth and viability of hematologic malignancies. Emerging data suggest a crucial
 involvement of the endothelial-specific Tie2 receptor and its antagonistic ligand Angiopoietin-2 (Ang-2) in this process.
 The purpose of this study was to elucidate whether the soluble domain of the Tie2 receptor (sTie2) predicts outcome in patients
 with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Serum levels of sTie2
 and Ang-2 were measured by ELISA in 181 AML patients before conditioning for HSCT. The median follow-up time was 22&amp;nbsp;months
 after HSCT. Pre-HSCT sTie2 levels were significantly higher in patients (median 2.2 (range 1.8–3.0)&amp;nbsp;ng/mL) compared to healthy
 controls (...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154645</comments>
            <pubDate>Wed, 06 Jan 2010 18:04:27 +0100</pubDate>
            <guid isPermaLink="false">3154645</guid>        </item>
        <item>
            <title>Acquired haemophilia caused by non-haemophilic factor VIII gene variants</title>
            <link>http://www.medworm.com/index.php?rid=3154644&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb212g463k8062w73%2F</link>
            <description>In conclusion, encounter of variant allogeneic FVIII presented on a suitable MHC background
 could be a risk factor for inhibitor formation.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0887-3Authors
		Andreas Tiede, Hannover Medical School Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation Feodor Lynen Str. 5 30625 Hannover GermanyRoswith Eisert, Hannover Medical School Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation Feodor Lynen Str. 5 30625 Hannover GermanyAndreas Czwalinna, Hannover Medical School Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation Feodor Lynen Str. 5 30625 Hannover GermanyWolfgang Miesbach, University Hospital Frankfurt Department of Internal Medicin...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154644</comments>
            <pubDate>Wed, 06 Jan 2010 18:04:27 +0100</pubDate>
            <guid isPermaLink="false">3154644</guid>        </item>
        <item>
            <title>Assessment of clopidogrel non-response by the PFA-100® system using the new test cartridge INNOVANCE® PFA P2Y</title>
            <link>http://www.medworm.com/index.php?rid=3154646&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn105876k3225x61t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Until now, the PFA-100® system has been considered unsuitable for monitoring clopidogrel efficacy. The authors evaluated platelet
 function in peripheral arterial occlusive disease (PAOD) patients using a new PFA-100® test cartridge (product name: INNOVANCE®
 PFA P2Y*) specifically designed for this purpose. Twenty-two stable PAOD patients on antithrombotic therapy with clopidogrel
 alone (n = 22) and 18 patients undergoing a peripheral catheter intervention, preliminarily treated with 100&amp;nbsp;mg/day of aspirin followed
 by co-administration of clopidogrel (loading dose 300&amp;nbsp;mg, maintenance dose 75&amp;nbsp;mg/day), were enrolled in this study. Defining
 non-responsiveness to clopidogrel as an aggregation response within the reference range (90% central interval...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154646</comments>
            <pubDate>Mon, 04 Jan 2010 18:15:46 +0100</pubDate>
            <guid isPermaLink="false">3154646</guid>        </item>
        <item>
            <title>High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study</title>
            <link>http://www.medworm.com/index.php?rid=3121473&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fuv503qw35u570275%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Therapeutic plasma exchange (PE) is the accepted therapy for thrombotic thrombocytopenic purpura (TTP). Because not all patients
 achieve remission, other treatment modalities have been used in addition to PE, but no randomized clinical trial evaluated
 their efficacy. The aim of this multicentric study was to compare the effectiveness of standard- versus high-dose methylprednisolone
 as an adjunctive treatment to PE in the acute phase of TTP. Sixty patients with idiopathic TTP were randomized to receive
 methylprednisolone 1&amp;nbsp;mg/kg/die intravenous or 10&amp;nbsp;mg/kg/die for 3&amp;nbsp;days, thereafter, 2.5&amp;nbsp;mg/kg/die in addition to PE. Both dosages
 of steroids were well tolerated. At the end of induction therapy (day&amp;nbsp;23), the percentage of patients failing to a...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3121473</comments>
            <pubDate>Wed, 23 Dec 2009 22:13:32 +0100</pubDate>
            <guid isPermaLink="false">3121473</guid>        </item>
        <item>
            <title>Acquired Hb H disease associated with elevated Hb F level in patient affected by primary myelofibrosis</title>
            <link>http://www.medworm.com/index.php?rid=3106021&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx1x470v2176g4073%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0878-4Authors
		Ciro Roberto Rinaldi, University Federico II Hematology Division, Department of Biochemistry and Medical Biotechnology 80131 Naples ItalyPaola Rinaldi, University Federico II Hematology Division, Department of Biochemistry and Medical Biotechnology 80131 Naples ItalyFabrizio Pane, University Federico II Hematology Division, Department of Biochemistry and Medical Biotechnology 80131 Naples ItalyAndrea Camera, University Federico II Hematology Division, Department of Biochemistry and Medical Biotechnology 80131 Naples ItalyCarmine Rinaldi, Laboratorio di Biologica Molecolare P.O. Marcianise ASL Caserta Caserta Italy
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (So...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3106021</comments>
            <pubDate>Fri, 18 Dec 2009 16:36:44 +0100</pubDate>
            <guid isPermaLink="false">3106021</guid>        </item>
        <item>
            <title>Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis</title>
            <link>http://www.medworm.com/index.php?rid=3106022&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn204kg426845q50x%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0884-6Authors
		Bruno Robibaro, Medical University Vienna Division of Pulmonary Medicine Waehringer Guertel 18-20 1090 Vienna AustriaAnna Kropfmueller, Medical University Vienna Division of Pulmonary Medicine Waehringer Guertel 18-20 1090 Vienna AustriaMathias Prokop, University Medical Center Utrecht Department of Radiology Heidelberglaan 100 3584 CX Utrecht The NetherlandsPaul Haber, Medical University Vienna Division of Pulmonary Medicine Waehringer Guertel 18-20 1090 Vienna AustriaHeinz Gisslinger, Medical University Vienna Division of Hematology and Blood Coagulation Waehringer Guertel 18-20 1090 Vienna Austria
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals o...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3106022</comments>
            <pubDate>Fri, 18 Dec 2009 16:36:43 +0100</pubDate>
            <guid isPermaLink="false">3106022</guid>        </item>
        <item>
            <title>Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study</title>
            <link>http://www.medworm.com/index.php?rid=3106023&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F631j10hw007264v0%2F</link>
            <description>Abstracts&amp;nbsp;&amp;nbsp;Pulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective
 analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect
 information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed
 P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34–79) years. Twenty-five of the patients
 (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients
 (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven
 pa...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3106023</comments>
            <pubDate>Fri, 18 Dec 2009 16:36:42 +0100</pubDate>
            <guid isPermaLink="false">3106023</guid>        </item>
        <item>
            <title>CTLA-4 +49A&gt;G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence</title>
            <link>http://www.medworm.com/index.php?rid=3106024&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft151tk97u5822x82%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Conflicting observations have been reported about the role of CTLA-4 gene polymorphisms in the clinical outcome of allogeneic hematopoietic stem cell transplantation (HSCT). We have investigated
 three polymorphisms of the CTLA-4 gene (−318C&amp;gt;T, +49A&amp;gt;G, CT60G&amp;gt;A) in 133 donor/recipient pairs who underwent HLA-matched sibling donor HSCT for hematological
 malignancies. We found no association of the clinical outcome of the HSCT with either recipient or donor −318C&amp;gt;T and CT60G&amp;gt;A
 polymorphisms. At variance, we found a significant association of donor +49A&amp;gt;G G/G genotype with longer overall survival (OS;
 log-rank test, P = 0.04), and the number of +49A&amp;gt;G G-alleles in the recipient with longer OS (P = 0.027), longer disease-free survival (P...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3106024</comments>
            <pubDate>Fri, 18 Dec 2009 07:05:45 +0100</pubDate>
            <guid isPermaLink="false">3106024</guid>        </item>
        <item>
            <title>The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact</title>
            <link>http://www.medworm.com/index.php?rid=3106025&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa18271285u544280%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chemokines are centrally involved in leukocyte migration, homing and haematopoiesis. Besides these physiological aspects,
 their role in pathological processes especially with respect to solid tumour and haematological neoplasias is well established.
 In this context, the focus was set here on disclosing their contribution in B cell chronic lymphocytic leukaemia (B-CLL),
 which is regarded as the most characteristic low-grade lymphoma. Up to now, it has been demonstrated that several chemokines
 are involved in migration of B-CLL cells to lymph nodes, secondary lymphoid organs and bone marrow. Moreover, some chemokines
 are known to have an anti-apoptotic effect and thus contribute to the survival of B-CLL cells. By interfering with both of
 these aspects, new therapeut...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3106025</comments>
            <pubDate>Fri, 18 Dec 2009 07:05:44 +0100</pubDate>
            <guid isPermaLink="false">3106025</guid>        </item>
        <item>
            <title>Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study</title>
            <link>http://www.medworm.com/index.php?rid=3106026&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F24651017300750q2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac involvement in patients with thalassemia intermedia (TI) is characterized by a high-output state and pulmonary hypertension,
 with systolic left ventricle function usually being preserved. Myocardial iron overload in patients with TI has not been extensively
 studied. We conducted a cross-sectional study of 49 Italian patients with TI. Patient charts were reviewed and data collected
 for transfusion and iron chelation history, status of the spleen, and comorbid illnesses or infections. Blood samples were
 obtained for assessment of hemoglobin, serum ferritin, and liver enzyme levels. Doppler echocardiography was done for all
 patients. Cardiac and hepatic iron levels were measured by magnetic resonance imaging T2*. The mean age was 40.5 ± 8.3&amp;nbsp;years,
 w...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3106026</comments>
            <pubDate>Thu, 17 Dec 2009 07:02:47 +0100</pubDate>
            <guid isPermaLink="false">3106026</guid>        </item>
        <item>
            <title>Monoclonal gammopathy of undetermined significance related pyoderma gangrenosum successfully treated with autologous peripheral blood stem cell transplantation</title>
            <link>http://www.medworm.com/index.php?rid=3098193&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F925r771777324n41%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0880-xAuthors
		Ching-Ming Chang, Taichung Veterans General Hospital Division of Hematology/Oncology, Department of Medicine 160, Section 3, Chungkang Road Taichung 407 Taiwan Republic of ChinaWen-Lee Hwang, Taichung Veterans General Hospital Division of Hematology/Oncology, Department of Medicine 160, Section 3, Chungkang Road Taichung 407 Taiwan Republic of ChinaZu-Yi Hsieh, Taichung Veterans General Hospital Division of Immunology, Department of Medicine Taichung Taiwan Republic of ChinaRen-Ching Wang, Taichung Veterans General Hospital Department of Pathology Taichung Taiwan Republic of ChinaChieh-Lin Teng, Taichung Veterans General Hospital Division of Hematology/Oncology, Department of Medicine 160, S...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3098193</comments>
            <pubDate>Tue, 15 Dec 2009 06:46:20 +0100</pubDate>
            <guid isPermaLink="false">3098193</guid>        </item>
        <item>
            <title>The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan</title>
            <link>http://www.medworm.com/index.php?rid=3086681&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr971wk422p787142%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Several reports have shown a different distribution of malignant lymphoma (ML) in Asian and Western populations. The purpose
 of our survey was to elucidate whether there are substantial differences in the frequencies of subtypes of ML between different
 geographical areas. All entities diagnosed as ML between June 1995 and December 2007 were selected according to the 2008 World
 Health Organization (WHO) classification and searched for clinical outcomes. The cases were retrieved and reviewed by a panel
 of clinical haematologists and haematopathologists. A total of 303 patients with ML were identified for retrospective analysis.
 Of the 303 patients with ML, 278 patients (91.7%) had non-Hodgkin’s lymphoma (NHL), and 25 (9.2%) had Hodgkin’s lymphoma.
 Of the 278 pat...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3086681</comments>
            <pubDate>Fri, 11 Dec 2009 06:52:02 +0100</pubDate>
            <guid isPermaLink="false">3086681</guid>        </item>
        <item>
            <title>Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis</title>
            <link>http://www.medworm.com/index.php?rid=3086682&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft65r5280982086n3%2F</link>
            <description>In conclusion,
 HDM/SCT can prolong overall survival in patients with MM/AL who are eligible to receive it.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0874-8Authors
		Saulius Girnius, Boston University School of Medicine Amyloid Treatment and Research Program Boston MA USADavid C. Seldin, Stem Cell Transplantation Program of the Section of Hematology-Oncology FGH 1007, 820 Harrison Avenue Boston MA 02118 USAMartha Skinner, Boston University School of Medicine Amyloid Treatment and Research Program Boston MA USAKathleen T. Finn, Stem Cell Transplantation Program of the Section of Hematology-Oncology FGH 1007, 820 Harrison Avenue Boston MA 02118 USAKaren Quillen, Stem Cell Transplantation Program of the Section of Hematology-Oncology FGH 1007, 820 Harrison...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3086682</comments>
            <pubDate>Thu, 10 Dec 2009 15:15:45 +0100</pubDate>
            <guid isPermaLink="false">3086682</guid>        </item>
        <item>
            <title>Hematoma of the iliopsoas muscle due to thrombocytopenia resulting from the administration of a third-generation cephalosporin</title>
            <link>http://www.medworm.com/index.php?rid=3086683&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj55k6430681818r6%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0872-xAuthors
		Makoto Onodera, Iwate Medical University Department of Critical Care Medicine 19-1 Uchimaru Morioka City Iwate 020-8505 JapanYasuhisa Fujino, Iwate Medical University Department of Critical Care Medicine 19-1 Uchimaru Morioka City Iwate 020-8505 JapanYoshihiro Inoue, Iwate Medical University Department of Critical Care Medicine 19-1 Uchimaru Morioka City Iwate 020-8505 JapanSatoshi Kikuchi, Iwate Medical University Department of Critical Care Medicine 19-1 Uchimaru Morioka City Iwate 020-8505 JapanShigeatsu Endo, Iwate Medical University Department of Critical Care Medicine 19-1 Uchimaru Morioka City Iwate 020-8505 Japan
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3086683</comments>
            <pubDate>Thu, 10 Dec 2009 15:15:44 +0100</pubDate>
            <guid isPermaLink="false">3086683</guid>        </item>
        <item>
            <title>Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)</title>
            <link>http://www.medworm.com/index.php?rid=3086684&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr4p0467830064n87%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Bortezomib (VELCADE®), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy,
 are highly effective in patients with multiple myeloma. We evaluated the responses and survival times of 35 patients treated
 with VTD followed by MPT. All patients were newly diagnosed and non-transplantation candidates. Patients received six cycles
 of VTD, which were followed by eight cycles of MPT. Approximately 97% of patients exhibited early responses to therapy, as
 early as the second cycle of VTD. Thirty percent of the responses were high quality, which was defined as a complete response
 (CR), a near-CR or a very good partial response. High-risk patients were defined as patients with any of the following aberrations:
 del(13), t(4;14...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3086684</comments>
            <pubDate>Thu, 10 Dec 2009 15:15:43 +0100</pubDate>
            <guid isPermaLink="false">3086684</guid>        </item>
        <item>
            <title>Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease</title>
            <link>http://www.medworm.com/index.php?rid=3064756&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe144m33678062t50%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0867-7Authors
		Agostina Siniscalchi, “Tor Vergata” University Department of Hematology, S. Eugenio Hospital Piazzale dell’Umanesimo, 10 00100 Rome ItalyTeresa Dentamaro, “Tor Vergata” University Department of Hematology, S. Eugenio Hospital Piazzale dell’Umanesimo, 10 00100 Rome ItalyAlessio Perrotti, “Tor Vergata” University Department of Hematology, S. Eugenio Hospital Piazzale dell’Umanesimo, 10 00100 Rome ItalyPaola Tatangelo, S. Eugenio Hospital Department of Nephrology Rome ItalyPaolo de Fabritiis, “Tor Vergata” University Department of Hematology, S. Eugenio Hospital Piazzale dell’Umanesimo, 10 00100 Rome ItalyTommaso Caravita, “Tor Vergata” University Department of Hematol...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064756</comments>
            <pubDate>Tue, 01 Dec 2009 20:57:07 +0100</pubDate>
            <guid isPermaLink="false">3064756</guid>        </item>
        <item>
            <title>Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure</title>
            <link>http://www.medworm.com/index.php?rid=3064758&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5777781714860t14%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0868-6Authors
		Yunya Luo, Central South University Division of Hematology, Institute of Molecular Hematology, Second Xiang-ya Hospital Changsha Hunan 410011 People’s Republic of ChinaGuangsen Zhang, Central South University Division of Hematology, Institute of Molecular Hematology, Second Xiang-ya Hospital Changsha Hunan 410011 People’s Republic of ChinaWenli Zuo, Central South University Division of Hematology, Institute of Molecular Hematology, Second Xiang-ya Hospital Changsha Hunan 410011 People’s Republic of ChinaWenli Zheng, Central South University Division of Hematology, Institute of Molecular Hematology, Second Xiang-ya Hospital Changsha Hunan 410011 People’s Republic of ChinaChongwen Dai, C...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064758</comments>
            <pubDate>Tue, 01 Dec 2009 20:57:05 +0100</pubDate>
            <guid isPermaLink="false">3064758</guid>        </item>
        <item>
            <title>Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3064757&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm1v14352v35j5876%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0866-8Authors
		Lisa Pieri, University of Florence UF di Ematologia, Dip. Area Critica Florence ItalyAlberto Bosi, University of Florence UF di Ematologia, Dip. Area Critica Florence ItalyAlessandro M. Vannucchi, University of Florence UF di Ematologia, Dip. Area Critica Florence Italy
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064757</comments>
            <pubDate>Tue, 01 Dec 2009 20:57:05 +0100</pubDate>
            <guid isPermaLink="false">3064757</guid>        </item>
        <item>
            <title>BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)</title>
            <link>http://www.medworm.com/index.php?rid=3041473&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg041464u11784317%2F</link>
            <description>In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0864-xAuthors
		Carlos Santamaría, Hospital Universitario Salamanca SpainMaría C. Chillón, Hospital Universitario Salamanca SpainRamón García-Sanz, Hospital Universitario Salamanca SpainCristina Pérez, Hospital Clínico San Carlos Madrid SpainMaría D. Caballero, Hospital Universitario Salamanca SpainMaría V. Mateos, Hospital Universitario Salamanca SpainFernando Ramos, Complejo Hospitalario de León and Ibiomed León SpainAlfonso García de Coca, Hospital Clínico de Valladolid Valladolid SpainJosé M. Alonso, Hospital Río Carrión de Palencia Palencia SpainPilar Giraldo, Hospital Miguel Servet Zaragoza SpainTeresa Bernal, Ho...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041473</comments>
            <pubDate>Fri, 27 Nov 2009 07:02:44 +0100</pubDate>
            <guid isPermaLink="false">3041473</guid>        </item>
        <item>
            <title>Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect</title>
            <link>http://www.medworm.com/index.php?rid=3032107&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F71m5l90vg172421g%2F</link>
            <description>We describe here molecular abnormalities found in nine Tunisian probands diagnosed with FXIIIA deficiency. The identification
 of the founder mutation and polymorphisms allowed a genetic counseling in relatives of these families, and the antenatal diagnosis
 is now available.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0863-yAuthors
		Nacim Louhichi, Faculty of Medicine of Sfax Human Molecular Genetic Laboratory Avenue Magida Boulila 3029 Sfax TunisiaMoez Medhaffar, Hédi Chaker de Sfax Service of Hematology. C.H.U Sfax TunisiaIkhlass HadjSalem, Faculty of Medicine of Sfax Human Molecular Genetic Laboratory Avenue Magida Boulila 3029 Sfax TunisiaEmna Mkaouar-Rebai, Faculty of Medicine of Sfax Human Molecular Genetic Laboratory Avenue Magida Boulila 3029 S...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3032107</comments>
            <pubDate>Tue, 24 Nov 2009 07:09:07 +0100</pubDate>
            <guid isPermaLink="false">3032107</guid>        </item>
        <item>
            <title>Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3098194&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa37nx3g76jr21p48%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients (pts) with fulminant progression (FPG) of multiple myeloma (MM) after autologous stem cell transplantation (ASCT)
 have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options
 are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with
 melphalan 100&amp;nbsp;mg/m2 (MEL 100) followed by PBSC support and consolidation therapy using regimens containing thalidomide (n = 16) or bortezomib (n = 15). The overall response rate (ORR) was 58% (18/31). After MEL 100, one patient achieved complete remission (3%), 26%
 of pts very good partial remission, 29% of pts partial remission, and 42% of pts stable disease. Progression within 3&amp;nbsp;m...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3098194</comments>
            <pubDate>Wed, 18 Nov 2009 19:15:05 +0100</pubDate>
            <guid isPermaLink="false">3098194</guid>        </item>
        <item>
            <title>Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3016285&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa37nx3g76jr21p48%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients (pts) with fulminant progression (FPG) of multiple myeloma (MM) after autologous stem cell transplantation (ASCT)
 have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options
 are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with
 melphalan 100&amp;nbsp;mg/m2 (MEL 100) followed by PBSC support and consolidation therapy using regimens containing thalidomide (n = 16) or bortezomib (n = 15). The overall response rate (ORR) was 58% (18/31). After MEL 100, one patient achieved complete remission (3%), 26%
 of pts very good partial remission, 29% of pts partial remission, and 42% of pts stable disease. Progression within 3&amp;nbsp;m...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016285</comments>
            <pubDate>Wed, 18 Nov 2009 19:15:05 +0100</pubDate>
            <guid isPermaLink="false">3016285</guid>        </item>
        <item>
            <title>Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study</title>
            <link>http://www.medworm.com/index.php?rid=3010190&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fvh10216215244805%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone
 was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment
 with bortezomib 1.3&amp;nbsp;mg/m2 intravenously on days 1, 4, 8, and 11; cyclophosphamide 150&amp;nbsp;mg/m2 orally on days 1–4; thalidomide 50&amp;nbsp;mg/day orally every day; and dexamethasone 20&amp;nbsp;mg/m2 intravenously on days 1, 4, 8, and 11. The overall best response rate was 88%, with 46% complete response, 9% very good partial
 response, and 33% partial response. After a median follow-up of 12.6&amp;nbsp;months, the median progression-free survival (PFS) was
 14.6&amp;nbsp;months with a 3-year PFS of 14% and the median overal...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010190</comments>
            <pubDate>Wed, 18 Nov 2009 00:06:17 +0100</pubDate>
            <guid isPermaLink="false">3010190</guid>        </item>
        <item>
            <title>Erratum to: Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=3010191&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc1232l6072r57428%2F</link>
            <description>Content Type Journal ArticleCategory ErratumDOI 10.1007/s00277-009-0860-1Authors
		Antonio R. Lucena-Araujo, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilDanielle L. Souza, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilFabio Morato de Oliveira, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilMariana Tereza Lira Benicio, Univer...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010191</comments>
            <pubDate>Wed, 18 Nov 2009 00:06:16 +0100</pubDate>
            <guid isPermaLink="false">3010191</guid>        </item>
        <item>
            <title>Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study</title>
            <link>http://www.medworm.com/index.php?rid=3010193&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb3g1501v464w8167%2F</link>
            <description>In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients.
 In addition, we evaluated the prognostic value of the World Health Organization classification as well as six prognostic scoring
 systems in these patients. The median follow-up time was 25.1&amp;nbsp;months (5.5–53.2). Of the 435 patients, 186 (42.8%) had died
 and 40 (9.2%) had progressed to acute myeloid leukemia. Multivariate analysis identified older age, higher percent of marrow
 blasts, and poor-risk IPSS cytogenetics as characteristics associated with worse survival and higher risk of leukemia transformation.
 Low platelets, hemoglobin, and mean corpuscular volume were independent factors associated only with worse survival. Among
 the 424 patients in whom the result...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010193</comments>
            <pubDate>Wed, 18 Nov 2009 00:06:14 +0100</pubDate>
            <guid isPermaLink="false">3010193</guid>        </item>
        <item>
            <title>Hyperlipidemic myeloma: review of 53 cases</title>
            <link>http://www.medworm.com/index.php?rid=3010192&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk64n070332355184%2F</link>
            <description>In conclusion, the clinical characteristics, the therapeutic options,
 and the pathophysiologic mechanisms of hyperlipidemic myeloma are comprehensively reported using the available data from all
 53 published cases in the literature.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0849-9Authors
		Benjamin Misselwitz, University Hospital Zürich Department of Internal Medicine Rämistr. 100 8091 Zürich SwitzerlandJeroen S. Goede, University Hospital Zürich Clinic of Haematology Rämistr. 100 8091 Zürich SwitzerlandBernhard C. Pestalozzi, University Hospital Zürich Clinic of Oncology Rämistr. 100 8091 Zürich SwitzerlandUrs Schanz, University Hospital Zürich Clinic of Haematology Rämistr. 100 8091 Zürich SwitzerlandJörg D. Seebach, University Hospital...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010192</comments>
            <pubDate>Wed, 18 Nov 2009 00:06:14 +0100</pubDate>
            <guid isPermaLink="false">3010192</guid>        </item>
        <item>
            <title>Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=2986736&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv885420485646r38%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0855-yAuthors
		Sumimasa Nagai, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanYasuhito Nannya, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanTsuyoshi Takahashi, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanMineo Kurokawa, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 Japan
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986736</comments>
            <pubDate>Tue, 10 Nov 2009 18:44:47 +0100</pubDate>
            <guid isPermaLink="false">2986736</guid>        </item>
        <item>
            <title>ABO discrepancy in an elderly patient with IgA kappa-type multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=2986735&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv67296576l84313m%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0858-8Authors
		So Young Kim, Kyung Hee University School of Medicine Department of Laboratory Medicine 1 Hoegi-dong, Dongdaemun-gu Seoul 130-702 Republic of KoreaSeung Hwan Oh, Inje University College of Medicine Department of Laboratory Medicine Gaegeum-dong, Busanjin-gu Busan 614-735 Republic of KoreaKyung Sun Park, Kyung Hee University School of Medicine Department of Laboratory Medicine 1 Hoegi-dong, Dongdaemun-gu Seoul 130-702 Republic of KoreaMin Jin Kim, Kyung Hee University School of Medicine Department of Laboratory Medicine 1 Hoegi-dong, Dongdaemun-gu Seoul 130-702 Republic of KoreaGayoung Lim, Kyung Hee University School of Medicine Department of Laboratory Medicine 1 Hoegi-dong, Dongdaemun-gu Seo...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986735</comments>
            <pubDate>Tue, 10 Nov 2009 18:44:47 +0100</pubDate>
            <guid isPermaLink="false">2986735</guid>        </item>
        <item>
            <title>Acquired erythropoietic protoporphyria</title>
            <link>http://www.medworm.com/index.php?rid=2982817&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F34jv277qu7611408%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0859-7Authors
		Daniel Blagojevic, Landesklinikum St. Poelten Karl Landsteiner Institute for Dermatological Research St. Poelten AustriaThomas Schenk, Landesklinikum St. Poelten Department of Internal Medicine I St. Poelten AustriaOskar Haas, Ambulatorium Medgen Vienna AustriaBrigitte Zierhofer, Landesklinikum St. Poelten Karl Landsteiner Institute for Dermatological Research St. Poelten AustriaChristophoros Konnaris, Medical University of Vienna Department of Gynecology and Obstetrics Vienna AustriaFranz Trautinger, Landesklinikum St. Poelten Karl Landsteiner Institute for Dermatological Research St. Poelten Austria
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2982817</comments>
            <pubDate>Mon, 09 Nov 2009 19:12:29 +0100</pubDate>
            <guid isPermaLink="false">2982817</guid>        </item>
        <item>
            <title>Resolution of invasive fungal sinusitis in immunocompromised patients: neutrophil count is crucial beside a combined medical and surgical approach</title>
            <link>http://www.medworm.com/index.php?rid=2971526&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk30hn7v118053j54%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0854-zAuthors
		Patrizia Zappasodi, Foundation IRCCS Policlinico San Matteo, University of Pavia Division of Haematology 27100 Pavia ItalyMarianna Rossi, Foundation IRCCS Policlinico San Matteo, University of Pavia Division of Haematology 27100 Pavia ItalyCarlo Castagnola, Foundation IRCCS Policlinico San Matteo, University of Pavia Division of Haematology 27100 Pavia ItalyFabio Pagella, Foundation IRCCS Policlinico San Matteo, University of Pavia Department of Otorhinolaryngology Pavia ItalyElina Matti, Foundation IRCCS Policlinico San Matteo, University of Pavia Department of Otorhinolaryngology Pavia ItalyCaterina Cavanna, Foundation IRCCS Policlinico San Matteo, University of Pavia Virology and Microbiolo...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971526</comments>
            <pubDate>Fri, 06 Nov 2009 18:55:30 +0100</pubDate>
            <guid isPermaLink="false">2971526</guid>        </item>
        <item>
            <title>Amyloid in bone marrow smears of patients affected by multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=2971527&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9k8v1132284v32p4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Systemic AL amyloidosis is associated with nearly 15% of cases of multiple myeloma, but data on the frequency and significance
 of amyloid deposits in the bone marrow of patients affected by multiple myeloma without clinical signs of systemic amyloidosis
 are scanty. Bone marrow smears of 166 unselected patients affected by multiple myeloma (126 at diagnosis and 40 after treatment)
 were stained with Congo red and studied by transmission and birefringence microscopy. Both focal and diffuse storages were
 considered positive. Overall, 67 patients were positive and 99 were negative to Congo red and apple-green birefringence. In
 particular, 51 of the 126 patients studied at diagnosis and 16 of the 40 patients with advanced disease were positive. Seventeen
 patients were r...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971527</comments>
            <pubDate>Thu, 05 Nov 2009 18:57:20 +0100</pubDate>
            <guid isPermaLink="false">2971527</guid>        </item>
        <item>
            <title>Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2965006&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgu44771521684472%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0851-2Authors
		Yu-Chung Huang, Taipei Veterans General Hospital Division of Hematology &amp; Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanZhi-Yi Xie, Taipei Veterans General Hospital Division of Hematology &amp; Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanHsiou-Shan Tseng, Taipei Veterans General Hospital Department of Radiology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanChing-Feng Yang, Taipei Veterans General Hospital Department of Pathology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanLiang-Tsai Hsiao, Taipei Veterans General Hospital Division of Hematology &amp; Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 Taiwan
	

	
		J...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2965006</comments>
            <pubDate>Tue, 03 Nov 2009 21:11:50 +0100</pubDate>
            <guid isPermaLink="false">2965006</guid>        </item>
        <item>
            <title>Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission</title>
            <link>http://www.medworm.com/index.php?rid=2947955&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5lp0870842817515%2F</link>
            <description>This study was done to assess outcomes and the impact of an early warning scoring system (EWS) and early involvement
 of ICU outreach teams. One hundred five haematology patients (haematopoietic stem cell transplant (HSCT) or non-HSCT) had
 114 admissions to ICU between April 2006 and August 2008 which coincided with hospital-wide implementation of EWS. The survival
 to ICU discharge was 56 (53%). Thirty-three (33%) patients were alive at 6&amp;nbsp;months giving a 1-year survival of 31%. Of the
 39 HSCT patients, nine were post-autologous and 30 post-allogeneic transplant. The survival to ICU discharge was 22 (56%)
 with 14 (36%) patients alive at 6&amp;nbsp;months. One year survival was 36%. Prior to the introduction of EWS and critical care outreach
 team (2004), survival to ICU discharge was 4...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947955</comments>
            <pubDate>Thu, 29 Oct 2009 19:38:16 +0100</pubDate>
            <guid isPermaLink="false">2947955</guid>        </item>
        <item>
            <title>Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression</title>
            <link>http://www.medworm.com/index.php?rid=2928857&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp28n8612n67x86q0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Lenalidomide consistently induces transfusion independence and complete cytogenetic response in patients with myelodysplastic
 syndromes with 5q deletion. Only limited information on long-term outcome is currently available. We performed a long-term
 follow-up analysis of 42 patients with low or intermediate risk myelodysplastic syndromes and 5q deletion treated with lenalidomide.
 At a median follow-up of 40&amp;nbsp;months, 58% of the patients achieved an erythroid response and 48% a cytogenetic response. Thirty-six
 percent of patients progressed into acute myeloid leukaemia. Most of them (87%) acquired chromosome aberrations in addition
 to the 5q deletion, i.e. underwent clonal evolution during leukaemogenesis. There were no clinical, cytological or cytogenetic
 marker...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2928857</comments>
            <pubDate>Fri, 23 Oct 2009 18:52:52 +0100</pubDate>
            <guid isPermaLink="false">2928857</guid>        </item>
        <item>
            <title>Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=2917960&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8125p571g03451r3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Serum albumin level, in association with serum interleukin-6 level, is a significant prognostic factor in multiple myeloma
 patients. The aim of this study was to determine any clinical factors associated with decreased serum albumin level. We retrospectively
 reviewed the records of 373 patients diagnosed with multiple myeloma at the Asan Medical Center, Seoul, Korea, between January
 1996 and March 2008. Patients were divided into two groups according to serum albumin level (above or below 3.5&amp;nbsp;g/dL, the
 prognostic cutoff value), and clinical parameters were compared between groups. We aimed to identify any clinical parameters
 associated with low serum albumin levels. The group with serum albumin &amp;lt;3.5&amp;nbsp;g/dL showed older patient age, lower hemoglobin
 leve...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2917960</comments>
            <pubDate>Wed, 21 Oct 2009 12:31:05 +0100</pubDate>
            <guid isPermaLink="false">2917960</guid>        </item>
        <item>
            <title>ABO discrepancy in a young Korean serviceman with common variable immunodeficiency</title>
            <link>http://www.medworm.com/index.php?rid=2917961&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy6m2t265tv267351%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0840-5Authors
		Seung Hwan Oh, Inje University Department of Laboratory Medicine, College of Medicine GaeGeum-dong, Busanjin-gu Busan 614-735 South KoreaCheol-In Kang, Sungkyunkwan University School of Medicine Division of Infectious Diseases, Samsung Medical Center 50 Ilwon-dong, Gangnam-gu Seoul 135-710 South KoreaJuwon Kim, Yonsei University College of Medicine Department of Laboratory Medicine 250 Seongsanno, Seodaemun-gu Seoul 120-752 South KoreaTae Sung Park, Kyung Hee University School of Medicine Department of Laboratory Medicine 1 Hoegi-dong, Dongdaemun-gu Seoul 130-702 South Korea
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2917961</comments>
            <pubDate>Wed, 21 Oct 2009 12:31:04 +0100</pubDate>
            <guid isPermaLink="false">2917961</guid>        </item>
        <item>
            <title>Plasmablastic crisis of Philadelphia chromosome-positive chronic myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=2917962&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy86t115524811304%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0852-1Authors
		Kalliopi N. Manola, National Center for Scientific Research (NCSR) “Demokritos” Laboratory of Cytogenetics 15310 Aghia Paraskevi Athens GreeceDespina Pantelidou, Medical School AUTH First Department of Internal Medicine, Hematology department Thessaloniki GreeceMaria Papaioannou, Medical School AUTH First Department of Internal Medicine, Hematology department Thessaloniki Greece
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2917962</comments>
            <pubDate>Wed, 21 Oct 2009 12:31:03 +0100</pubDate>
            <guid isPermaLink="false">2917962</guid>        </item>
        <item>
            <title>18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract</title>
            <link>http://www.medworm.com/index.php?rid=2917963&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F65767r6071463238%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0842-3Authors
		Adrian Tempescul, CHU Brest Department of Clinical Hematology, Institute of Cancerology and Hematology Avenue Foch 29609 Brest FranceSolene Querellou, CHU Brest Department of Nuclear Medicine Avenue Foch 29609 Brest FranceJean-Christophe Ianotto, CHU Brest Department of Clinical Hematology, Institute of Cancerology and Hematology Avenue Foch 29609 Brest FranceSylvie Boisramé, CHU Brest Department of Odontology Avenue Foch 29609 Brest FranceGerald Valette, CHU Brest Department of ORL Avenue Foch 29609 Brest FranceChristian Berthou, CHU Brest Department of Clinical Hematology, Institute of Cancerology and Hematology Avenue Foch 29609 Brest France
	

	
		Journal Annals of HematologyOnline ISSN 1...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2917963</comments>
            <pubDate>Wed, 21 Oct 2009 09:05:07 +0100</pubDate>
            <guid isPermaLink="false">2917963</guid>        </item>
        <item>
            <title>Vitamin D deficiency and anemia: a cross-sectional study</title>
            <link>http://www.medworm.com/index.php?rid=2917964&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa4722230888951m1%2F</link>
            <description>This study demonstrates an association of vitamin D deficiency and a greater risk of anemia, lower mean hemoglobin,
 and higher usage of erythrocyte-stimulating agents. Future randomized studies are warranted to examine whether vitamin D directly
 affects erythropoiesis.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0850-3Authors
		John J. Sim, Kaiser Permanente Los Angeles Medical Center Division of Nephrology and Hypertension 4700 Sunset Blvd., 2nd Floor Nephrology Los Angeles CA 90027 USAPeter T. Lac, Kaiser Permanente Los Angeles Medical Center Division of Nephrology and Hypertension 4700 Sunset Blvd., 2nd Floor Nephrology Los Angeles CA 90027 USAIn Lu A. Liu, Kaiser Permanente Southern California Department of Research and Evaluation 100 S. Los Robles ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2917964</comments>
            <pubDate>Tue, 20 Oct 2009 16:32:31 +0100</pubDate>
            <guid isPermaLink="false">2917964</guid>        </item>
        <item>
            <title>Glutathione S-transferase gene deletions and their effect on iron status in HbE/β thalassemia patients</title>
            <link>http://www.medworm.com/index.php?rid=2906436&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk623r33413q931w4%2F</link>
            <description>This study was aimed to compare the prevalence of GST deletions in 240&amp;nbsp;HbE/β thalassemia patients with 100 controls and to
 determine role of deletions on iron overload. We observed significantly higher frequency of GSTT1 (P = 0.001) and GSTT1/GSTM1 (P = 0.03) in comparison to controls. Patients who had null genotype for both the alleles, i.e., GSTT1/GSTM1 had significantly
 higher levels of serum iron (P = 0.007) and serum ferritin (P = 0.001) than patients with normal genotype for GST deletions. This is the first study to prove the role of GST gene deletions
 with iron overload in HbE/β thalassemia.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0847-yAuthors
		Vineeta Sharma, I.R.C.H. Building (first floor), All India Institute of M...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906436</comments>
            <pubDate>Fri, 16 Oct 2009 18:01:09 +0100</pubDate>
            <guid isPermaLink="false">2906436</guid>        </item>
        <item>
            <title>Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells</title>
            <link>http://www.medworm.com/index.php?rid=2896486&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx06337x8344r0l83%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Natural killer (NK) cells contribute to the graft-versus-leukemia effect after allogeneic stem cell transplantation. However,
 the efficacy of NK cell-mediated tumor cell lysis is limited due to target cell resistance, and target cell-induced apoptosis
 (TiA) was proposed to contribute to differences in susceptibility to NK cells. Here we analyzed the effects of target cells
 on the apoptosis of cytokine-activated NK cells in vitro. We found no association of target cell susceptibility and TiA of
 NK cells in an array of human and murine target-effector cell combinations. Incubation of NK cells with caspase inhibitors
 blocked TiA incompletely, indicating that TiA is partly based on caspase-independent mechanisms. Modulating NK cell susceptibility
 against TiA by caspas...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896486</comments>
            <pubDate>Tue, 13 Oct 2009 08:15:30 +0100</pubDate>
            <guid isPermaLink="false">2896486</guid>        </item>
        <item>
            <title>Idiopathic neutropenia with fewer than 5% dysplasia may be a distinct entity of idiopathic cytopenia of undetermined significance</title>
            <link>http://www.medworm.com/index.php?rid=2896485&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx507718m231p7263%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0845-0Authors
		Keiko Ando, Tokyo Medical University The First Department of Internal Medicine (Hematology Division) 6-7-1 Nishishinjuku, Shinjuku-ku Tokyo 160-0023 JapanAtsushi Kodama, Tokyo Medical University Division of Cytogenetics, Central Laboratory Tokyo JapanTamiko Iwabuchi, Tokyo Medical University The First Department of Internal Medicine (Hematology Division) 6-7-1 Nishishinjuku, Shinjuku-ku Tokyo 160-0023 JapanJunko H. Ohyashiki, Tokyo Medical University Intractable Disease Research Center Tokyo JapanKazuma Ohyashiki, Tokyo Medical University The First Department of Internal Medicine (Hematology Division) 6-7-1 Nishishinjuku, Shinjuku-ku Tokyo 160-0023 Japan
	

	
		Journal Annals of HematologyOnli...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896485</comments>
            <pubDate>Tue, 13 Oct 2009 08:15:30 +0100</pubDate>
            <guid isPermaLink="false">2896485</guid>        </item>
        <item>
            <title>Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children</title>
            <link>http://www.medworm.com/index.php?rid=2896484&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff147477rgn046276%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Subcutaneous (sc) administration of anti-d seems to offer the same efficacy as intravenous administration but with less side effects. Here we report our experience
 with sc anti-d for pediatric immune thrombocytopenia (ITP). A total of 12 children with a median age of 11.2&amp;nbsp;years had been treated by sc
 anti-d. They received a median of 2 sc anti-d applications (range 1–31) with a dosage of 250–375&amp;nbsp;IE/kg body weight. Only in one out of a total of 102 single applications,
 a minimal and self-limited side effect (chills) had been observed. The mean platelet count was almost doubled after sc anti-d (p &amp;lt; 0.0001). After a median follow-up of 11.4&amp;nbsp;months, all patients are alive without major bleeding and stay well. We conclude
 that sc anti-d is not o...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896484</comments>
            <pubDate>Tue, 13 Oct 2009 08:15:30 +0100</pubDate>
            <guid isPermaLink="false">2896484</guid>        </item>
        <item>
            <title>Postallogeneic hematopoietic stem cell transplantation relapse of acute myeloid leukemia presenting with salivary gland myelosarcoma</title>
            <link>http://www.medworm.com/index.php?rid=2880573&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc130087545r2466n%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0843-2Authors
		Yu-Hsuan Lai, Kaohsiung Medical University Hospital Division of Hematology-Oncology, Department of Internal Medicine Kaohsiung TaiwanChao-Sung Chang, Kaohsiung Medical University Hospital Division of Hematology-Oncology, Department of Internal Medicine Kaohsiung TaiwanYi-Chang Liu, Kaohsiung Medical University Hospital Division of Hematology-Oncology, Department of Internal Medicine Kaohsiung TaiwanTa-Chih Liu, Kaohsiung Medical University Hospital Division of Hematology-Oncology, Department of Internal Medicine Kaohsiung Taiwan
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2880573</comments>
            <pubDate>Fri, 09 Oct 2009 06:06:23 +0100</pubDate>
            <guid isPermaLink="false">2880573</guid>        </item>
        <item>
            <title>Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS)</title>
            <link>http://www.medworm.com/index.php?rid=2877754&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm5q8153724684v32%2F</link>
            <description>In conclusion, our study showed altered expression of genes involved in apoptosis and cell cycle in MDS
 and increased expression of cyclin D1 in patients with CMML.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0835-2Authors
		Christina Economopoulou, Attikon University Hospital, 2nd Propedeutic Clinic of Internal Medicine 1 Rimini Str., Haidari Athens GreeceVassiliki Pappa, Attikon University Hospital, 2nd Propedeutic Clinic of Internal Medicine 1 Rimini Str., Haidari Athens GreeceSotiris Papageorgiou, Attikon University Hospital, 2nd Propedeutic Clinic of Internal Medicine 1 Rimini Str., Haidari Athens GreeceFrieda Kontsioti, Attikon University Hospital, 2nd Propedeutic Clinic of Internal Medicine 1 Rimini Str., Haidari Athens GreecePanagiota Economopoul...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2877754</comments>
            <pubDate>Thu, 08 Oct 2009 07:14:21 +0100</pubDate>
            <guid isPermaLink="false">2877754</guid>        </item>
        <item>
            <title>An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia</title>
            <link>http://www.medworm.com/index.php?rid=2870258&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2038812l45m27462%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The most common mutation of the HFE gene C282Y has shown a risk association with childhood acute lymphoblastic leukemia (ALL) in Welsh and Scottish case–control
 studies. This finding has not been replicated outside Britain. Here, we present a thorough analysis of the HFE gene in a panel of HLA homozygous reference cell lines and in the original population sample from South Wales (117 childhood
 ALL cases and 414 newborn controls). The 21 of 24 variants analyzed were from the HFE gene region extending 52&amp;nbsp;kb from the histone gene HIST1H1C to HIST1H1T. We identified the single-nucleotide polymorphism (SNP) rs807212 as a tagging SNP for the most common HFE region haplotype, which contains wild-type alleles of all HFE variants examined. This intergenic SNP rs807212 y...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2870258</comments>
            <pubDate>Tue, 06 Oct 2009 12:44:57 +0100</pubDate>
            <guid isPermaLink="false">2870258</guid>        </item>
        <item>
            <title>Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major</title>
            <link>http://www.medworm.com/index.php?rid=2864031&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc66654794662955j%2F</link>
            <description>This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded
 patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox
 therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2 ± 10.8 to 21.5 ± 12.8&amp;nbsp;ms (+25.0%;
 P = 0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235&amp;nbsp;ng/mL (−23.0%; P = 0.001), and mean liver iron concentration from 24.2 ± 9.0 to 17.6 ± 12.9&amp;nbsp;mg&amp;nbsp;Fe/g dry weight (−27.1%; P = 0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients
 with a baseline cardiac T2* of &amp;lt;10&amp;nbsp;m...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2864031</comments>
            <pubDate>Thu, 01 Oct 2009 18:31:42 +0100</pubDate>
            <guid isPermaLink="false">2864031</guid>        </item>
        <item>
            <title>Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia</title>
            <link>http://www.medworm.com/index.php?rid=2864030&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl122861625nv75u6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to describe the characteristics and outcome in a group of pediatric patients with hematological
 malignancies who developed hemophagocytosis at diagnosis or during the disease course. Eight patients with hematological malignancy
 and associated hemophagocytosis were included. The initial diagnosis was juvenile myelomonocytic leukemia (JMML) in five,
 nonlymphoblastic leukemia (ANLL) in two, and T-cell lymphoma associated with myeloproliferative syndrome in one patient. Hemophagocytosis
 was concomitantly present at the time of diagnosis of the primary disease in four of the five patients with JMML and in the
 two patients with ANLL. Three had abnormalities related to chromosome 8 [(trisomy 8, monosomy 8, and t (8;13) (p11; p12)], and one had in...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2864030</comments>
            <pubDate>Thu, 01 Oct 2009 18:31:42 +0100</pubDate>
            <guid isPermaLink="false">2864030</guid>        </item>
        <item>
            <title>Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate</title>
            <link>http://www.medworm.com/index.php?rid=2848585&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9x65h487115636l3%2F</link>
            <description>This study provides the first direct evidence that Beriplex®
 P/N can be rapidly infused for emergency coumarin therapy reversal without altering safety or effectiveness.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0830-7Authors
		Ingrid Pabinger, Medical University Vienna Department of Internal Medicine, Division of Haematology and Haemostaseology Vienna AustriaAndreas Tiede, Hannover Medical School Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation Hannover GermanyUwe Kalina, Hemophilia/Critical Care, CSL Behring GmbH Clinical Research &amp; Development Marburg GermanySigurd Knaub, Hemophilia/Critical Care, CSL Behring GmbH Clinical Research &amp; Development Marburg GermanyReinhard Germann, Academic Teaching Hospital Feldkirch Depa...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2848585</comments>
            <pubDate>Tue, 29 Sep 2009 04:04:59 +0100</pubDate>
            <guid isPermaLink="false">2848585</guid>        </item>
        <item>
            <title>Reduction of serum free light chains predict renal recovery</title>
            <link>http://www.medworm.com/index.php?rid=2848586&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5352371527244xg3%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0836-1Authors
		Colin A. Hutchison, University Hospital Birmingham Renal Institute of Birmingham, Department of Nephrology Birmingham B152TH UK
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2848586</comments>
            <pubDate>Mon, 28 Sep 2009 14:33:06 +0100</pubDate>
            <guid isPermaLink="false">2848586</guid>        </item>
        <item>
            <title>Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response</title>
            <link>http://www.medworm.com/index.php?rid=2848587&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl6r57527l1j12771%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis
 activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor
 (HGF), and inhibitors, including endostatin, thrombospondin-1 (TSP-1), and angiostatin in the peripheral and bone marrow blood
 of MM patients at diagnosis and after high-dose chemotherapy. We have analyzed 96 patients with secretory MM. Serial measurements
 of angiogenesis factors/inhibitors were analyzed in the plasma by subgroups based on the best treatment response. Concentrations
 of angiogenic factors were determined in the peripheral blood and bone marrow plasma. There were significant decreases of
 VEGF and...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2848587</comments>
            <pubDate>Mon, 28 Sep 2009 14:32:46 +0100</pubDate>
            <guid isPermaLink="false">2848587</guid>        </item>
        <item>
            <title>Stomatocytosis heralding a case of acute Wilsonian crisis</title>
            <link>http://www.medworm.com/index.php?rid=2835142&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5447112t38632748%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0832-5Authors
		Amit R. Mehta, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School Department of Medicine New Brunswick NJ USAGratian Salaru, The Cancer Institute of New Jersey New Brunswick NJ USAJonathan S. Harrison, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School Department of Medicine New Brunswick NJ USA
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2835142</comments>
            <pubDate>Thu, 24 Sep 2009 14:34:08 +0100</pubDate>
            <guid isPermaLink="false">2835142</guid>        </item>
        <item>
            <title>Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients</title>
            <link>http://www.medworm.com/index.php?rid=2810959&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn877x64848470008%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0833-4Authors
		Mats Kalin, Karolinska University Hospital Solna and Institutet Department of Medicine, Division of Infectious Diseases Stockholm SwedenSigurdur Yngvi Kristinsson, Karolinska University Hospital Solna Department of Medicine, Division of Hematology SE-171 76 Stockholm SwedenHonar Cherif, Karolinska University Hospital Solna Department of Medicine, Division of Hematology SE-171 76 Stockholm SwedenMarianne Lebbad, Swedish Institute for Infectious Disease Control Stockholm SwedenMagnus Björkholm, Karolinska University Hospital Solna Department of Medicine, Division of Hematology SE-171 76 Stockholm Sweden
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810959</comments>
            <pubDate>Fri, 18 Sep 2009 16:11:23 +0100</pubDate>
            <guid isPermaLink="false">2810959</guid>        </item>
        <item>
            <title>Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=2810960&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx8274413441544w5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multiple myeloma is a malignant B-cell neoplasm that involves the skeleton in approximately 80% of the patients. With an average
 age of 60&amp;nbsp;years and a 5-years survival of nearly 45% Brenner et al. (Blood 111:2516–2520, 35) the onset is to be classified as occurring still early in life while the disease can be very aggressive and debilitating.
 In the last decades, several new imaging techniques were introduced. The aim of this review is to compare the different techniques
 such as radiographic survey, multidetector computed tomography (MDCT), whole-body magnetic resonance imaging (WB-MRI), fluorodeoxyglucose
 positron emission tomography- (FDG-PET) with or without computed tomography (CT), and 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) scintigraphy. We conclud...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810960</comments>
            <pubDate>Thu, 17 Sep 2009 23:35:18 +0100</pubDate>
            <guid isPermaLink="false">2810960</guid>        </item>
        <item>
            <title>Decreased hemolysis following administration of antioxidant—fermented papaya preparation (FPP) to a patient with PNH</title>
            <link>http://www.medworm.com/index.php?rid=2810961&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc671j729658xr5qw%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0821-8Authors
		Hussam Ghoti, Edit Wolfson Medical Center Department of Hematology Holon IsraelHanna Rosenbaum, Rambam Medical Center Department of Hematology and Bone Marrow Transplantation Haifa IsraelEitan Fibach, Hadassah–Hebrew University Medical Center Department of Hematology Jerusalem IsraelEliezer A. Rachmilewitz, Edit Wolfson Medical Center Department of Hematology Holon Israel
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810961</comments>
            <pubDate>Wed, 16 Sep 2009 12:27:33 +0100</pubDate>
            <guid isPermaLink="false">2810961</guid>        </item>
        <item>
            <title>Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R</title>
            <link>http://www.medworm.com/index.php?rid=2810962&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7182p6460102194%2F</link>
            <description>In conclusion, curcumin reversed multidrug
 resistance of MOLP-2/R through inhibition of FA/BRCA pathway. The possible mechanisms include (1) reduction of DNA damage
 repair and stimulation of apoptosis of tumor cells through inhibition of FA/BRCA pathway, which is important for DNA repair,
 and (2) achievement of high concentration in target cells. Curcumin may be a safe reversal agent of multidrug resistance with
 low-dose DNA cross-linking agents.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0831-6Authors
		Hui Xiao, Zhongnan Hospital of Wuhan University Department of Hematology No.169 Donghu Road Wuhan 430071 ChinaQi Xiao, Yanqiao Hospital of Yunyang Medical College Department of Internal Medicine Shiyan 442000 ChinaKejian Zhang, Zhongnan Hospital of W...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810962</comments>
            <pubDate>Wed, 16 Sep 2009 12:27:32 +0100</pubDate>
            <guid isPermaLink="false">2810962</guid>        </item>
        <item>
            <title>Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=2767414&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9144w37447211428%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0817-4Authors
		Antonio R. Lucena-Araujo, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilDanielle L. Souza, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilFabio Morato de Oliveira, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilMariana Tereza Lira Be...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767414</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:52 +0100</pubDate>
            <guid isPermaLink="false">2767414</guid>        </item>
        <item>
            <title>Long-term response to deferiprone therapy in Asian Indians</title>
            <link>http://www.medworm.com/index.php?rid=2767413&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F93445l285170j3l4%2F</link>
            <description>Content Type Journal ArticleCategory ErratumDOI 10.1007/s00277-009-0825-4Authors
		Inusha Panigrahi, Post-Graduate Institute of Medical Education &amp; Research (PGIMER) Hemato-Oncology &amp; Genetics Units, Department of Pediatrics, Advanced Pediatrics Centre (APC) Chandigarh IndiaRam K. Marwaha, Post-Graduate Institute of Medical Education &amp; Research (PGIMER) Hemato-Oncology &amp; Genetics Units, Department of Pediatrics, Advanced Pediatrics Centre (APC) Chandigarh IndiaRashmi R. Das, Post-Graduate Institute of Medical Education &amp; Research (PGIMER) Hemato-Oncology &amp; Genetics Units, Department of Pediatrics, Advanced Pediatrics Centre (APC) Chandigarh India
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767413</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:52 +0100</pubDate>
            <guid isPermaLink="false">2767413</guid>        </item>
        <item>
            <title>Compound heterozygosity of Hb Hamilton and de novo mutated HbM Saskatoon</title>
            <link>http://www.medworm.com/index.php?rid=2767416&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F81207528183l6860%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0828-1Authors
		Saskia Brunner-Agten, Kantonsspital Aarau Zentrum für Labormedizin 5001 Aarau SwitzerlandMartin Hergersberg, Kantonsspital Aarau Zentrum für Labormedizin 5001 Aarau SwitzerlandRoberto Herklotz, Kantonsspital Aarau Zentrum für Labormedizin 5001 Aarau SwitzerlandAndreas Hirt, Inselspital Bern Kinderpoliklinik 3010 Bern SwitzerlandAndreas R. Huber, Kantonsspital Aarau Zentrum für Labormedizin 5001 Aarau Switzerland
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767416</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:49 +0100</pubDate>
            <guid isPermaLink="false">2767416</guid>        </item>
        <item>
            <title>Compound heterozygosity for HbD Punjab and polyadenylation signal mutation causes clinically asymptomatic mild hypochromia and microcytosis</title>
            <link>http://www.medworm.com/index.php?rid=2767415&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq7723837j228v2g5%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0827-2Authors
		Katta Mohan Girisha, Kasturba Medical College Genetics Clinic, Department of Pediatrics Manipal 576104 IndiaSaadi Abdul Vahab, Manipal University Manipal Life Sciences Center Manipal 576104 IndiaAshwin B. Dalal, Center for DNA Fingerprinting and Diagnostics Hyderabad IndiaP. M. Gopinath, Manipal University Manipal Life Sciences Center Manipal 576104 IndiaK. Satyamoorthy, Manipal University Manipal Life Sciences Center Manipal 576104 India
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767415</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:49 +0100</pubDate>
            <guid isPermaLink="false">2767415</guid>        </item>
        <item>
            <title>Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes</title>
            <link>http://www.medworm.com/index.php?rid=2767418&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff3034140g2731756%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Myelodysplastic syndromes (MDS) are characterized by genetic instability which is associated with abnormal DNA repair mechanisms.
 The most lethal type of DNA damage are double strand DNA breaks (DSBs), which are mainly repaired by Non Homologous End Joining
 Mechanism (NHEJ), whose core enzyme components include the Ku70/Ku80 heterodimer, DNA–PKcs, XRCC4 and DNA Ligase IV. The aim
 of the present study was the analysis of expression of proteins required for NHEJ in bone marrow cells of adult de novo MDS
 and their association with clinical characteristics and prognosis. Our analysis included 48 cases of MDS; 19 RA, 5 RARS, 19
 RAEB, 3 RAEB-T, 1 CMML, 1 transformation to AML according to FAB classification. The expression of the enzymes Ku70, Ku80,
 XRCC4, DNA-PKcs an...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767418</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:47 +0100</pubDate>
            <guid isPermaLink="false">2767418</guid>        </item>
        <item>
            <title>DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance</title>
            <link>http://www.medworm.com/index.php?rid=2767417&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp11p8437p3267671%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Aberrant DNA methylation is considered an important epigenetic mechanism for gene inactivation. Monoclonal gammopathy of undetermined
 significance (MGUS) is believed to be a precursor of multiple myeloma (MM). We have analyzed methylation status of p15
 
 INK4B
 , p16
 
 INK4A
 , ARF, SOCS-1, p27
 
 KIP1
 , RASSF1A, and TP73 genes in bone marrow DNA samples from 21 MGUS and 44 MM patients, in order to determine the role of aberrant promoter methylation
 as one of the steps involved in the progression of MGUS to MM. Methylation specific polymerase chain reaction assay followed
 by DNA sequencing of the resulting product was performed. SOCS-1 gene methylation was significantly more frequent in MM (52%) than in MGUS (14%; p = 0,006). Methylation frequencies of TP73, A...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767417</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:47 +0100</pubDate>
            <guid isPermaLink="false">2767417</guid>        </item>
        <item>
            <title>Acute lymphoblastic leukemia masquerading as juvenile rheumatoid arthritis: diagnostic pitfall and association with survival</title>
            <link>http://www.medworm.com/index.php?rid=2767420&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6433jq1506148148%2F</link>
            <description>This study was designed to identify ALL patients with initial diagnosis of JRA, compare their
 clinicolaboratory characteristics and outcome with other ALL patients treated at our center. Case records of 762 patients
 with ALL were analyzed. Information regarding the clinical-demographic profile, therapy and outcome were recorded. Of the
 children, 49 (6.4%) had initial presentation mimicking JRA. Asymmetric oligoarthritis was the most common pattern of joint
 involvement. Majority presented with fever, pallor, arthritis, night pain, and bone pain. None of the routine prognostic factors
 including age, gender, lymphadenopathy, hepatosplenomegaly, total leukocytes count (TLC), and platelet count were significantly
 associated with relapse/death. The mean symptom-presentation interval (SPI),...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767420</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:46 +0100</pubDate>
            <guid isPermaLink="false">2767420</guid>        </item>
        <item>
            <title>Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab</title>
            <link>http://www.medworm.com/index.php?rid=2767419&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn87wu85217142n55%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0819-2Authors
		Marco Tuccori, University of Pisa Division of Pharmacology and Chemotherapy, Department of Internal Medicine Via Roma 55 56126 Pisa ItalyDaniele Focosi, University of Pisa Division of Haematology, Department of Oncology, Transplantations and New Technologies in Medicine Pisa ItalyFabrizio Maggi, University of Pisa Virology Section and Retrovirus Centre, Department of Experimental Pathology Pisa ItalyMirco Cosottini, University of Pisa Department of Neuroscience Pisa ItalyBarbara Meini, Tuscan Regional Centre for Pharmacovigilance Florence ItalyFabio Lena, Tuscan Regional Centre for Pharmacovigilance Florence ItalyCorrado Blandizzi, University of Pisa Division of Pharmacology and Chemotherapy, ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767419</comments>
            <pubDate>Thu, 03 Sep 2009 06:23:46 +0100</pubDate>
            <guid isPermaLink="false">2767419</guid>        </item>
        <item>
            <title>Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2767421&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr12m72w27215j825%2F</link>
            <description>We report here a single-centre retrospective
 outcome analysis of second-line immunochemotherapy with rituximab. In 28 patients with relapsed or refractory diffuse large
 B cell lymphomas, first-line immunochemotherapy had induced objective responses in 18 patients. Nine of 28 patients responded
 to rituximab containing salvage therapy, leading to a median overall survival of 243&amp;nbsp;days after start of second immunochemotherapy.
 Long-term disease free survivors (1,260 and 949&amp;nbsp;days) were restricted to the group of twelve patients that had received allogeneic
 stem cell transplantation as consolidation therapy. In 21 patients with relapsed mantle cell lymphomas (MCL), 19 patients
 had reached remissions with first-line therapy. Of those, 16 patients experienced responses to salvage t...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767421</comments>
            <pubDate>Tue, 01 Sep 2009 16:47:51 +0100</pubDate>
            <guid isPermaLink="false">2767421</guid>        </item>
        <item>
            <title>Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil</title>
            <link>http://www.medworm.com/index.php?rid=2745012&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbh7x580uw3831463%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0824-5Authors
		Uwe Platzbecker, Universitätsklinikum “Carl Gustav Carus” Dresden Medizinische Klinik und Poliklinik I 01307 Dresden GermanyCarlo Aul, St. Johannes Hospital Duisburg Duisburg GermanyGerhard Ehninger, Universitätsklinikum “Carl Gustav Carus” Dresden Medizinische Klinik und Poliklinik I 01307 Dresden GermanyAristoteles Giagounidis, St. Johannes Hospital Duisburg Duisburg Germany
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2745012</comments>
            <pubDate>Fri, 28 Aug 2009 16:57:52 +0100</pubDate>
            <guid isPermaLink="false">2745012</guid>        </item>
        <item>
            <title>Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts</title>
            <link>http://www.medworm.com/index.php?rid=2745013&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh707348u01773572%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic myeloid leukemia patients with different BCR-ABL transcripts might respond differently to Imatinib mesylate. This
 prompted us to study BCR-ABL transcripts in chronic myeloid leukemia (CML) patients and their correlation with response to
 Imatinib. Eighty-seven chronic phase CML patients (median age, 35&amp;nbsp;years; range, 13–62&amp;nbsp;years; M/F, 59:28) were included in
 this study; 57 patients had received interferon-α and/or hydroxyurea, and 30 were previously untreated. All patients received
 Imatinib mesylate (Gleevec) 400&amp;nbsp;mg daily. Complete hematological remission rate and major cytogenetic response (CGR) rates
 were 99% and 72%, respectively. B3a2 transcript was present in 53% of patients, b2a2 in 39%, and both transcripts in 8% of
 patients. Twenty ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2745013</comments>
            <pubDate>Fri, 28 Aug 2009 16:57:49 +0100</pubDate>
            <guid isPermaLink="false">2745013</guid>        </item>
        <item>
            <title>Frequencies of non-Hodgkin’s lymphoma subtypes in Kuwait: comparisons between different ethnic groups</title>
            <link>http://www.medworm.com/index.php?rid=2742732&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2pvx882010368r2v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;There is a wide variation in the prevalence of various subtypes of non-Hodgkin’s lymphoma worldwide. The aim of this study
 was to determine the relative frequency of different subtypes of non-Hodgkin’s lymphoma in Kuwait based on the Revised European–American
 Lymphoma (REAL) classification. From 1998 to 2006, 738 subjects were included that were registered with non-Hodgkin’s lymphoma
 in the population-based cancer registry at the Kuwait Cancer Control Center. Expert pathologists reviewed histological slides
 from all subjects. We performed detailed immunohistochemical studies and classified subjects based on the REAL classification.
 The prevalence of different types of non-Hodgkin's lymphoma was determined based on age, sex, site of disease, and ethnicity.
 ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2742732</comments>
            <pubDate>Thu, 27 Aug 2009 16:33:11 +0100</pubDate>
            <guid isPermaLink="false">2742732</guid>        </item>
        <item>
            <title>Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide</title>
            <link>http://www.medworm.com/index.php?rid=2731976&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk283765370nwl878%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The frequency of thromboembolic events (TE) in Caucasian patients with multiple myeloma (MM) receiving thalidomide as the
 initial treatment has been reported to be 10~58% without prophylactic anticoagulation. Korean MM patients treated with thalidomide
 were studied to determine the frequency of TE and associated risk factors. A retrospective medical record review of the Korean
 MM registry from 25 centers in Korea between 2003 and 2007 was performed. We assessed the incidence of arterial and venous
 TE and the associated clinical parameters. Three hundred and sixty MM patients (median age 61&amp;nbsp;years, range 32–88&amp;nbsp;years) received
 thalidomide treatment. Fourteen patients (3.9%) developed TE: 12 had venous and two had arterial locations. The sites for
 the veno...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2731976</comments>
            <pubDate>Mon, 24 Aug 2009 16:51:32 +0100</pubDate>
            <guid isPermaLink="false">2731976</guid>        </item>
        <item>
            <title>Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia</title>
            <link>http://www.medworm.com/index.php?rid=2731975&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F401h260142k22361%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Aplastic anemia (AA) is most frequently due to autoimmune attack on its own stem cells. Alemtuzumab is a monoclonal antibody
 which recognizes the CD52 antigen on the surface of T and B cells. It has proved useful in autoimmune diseases, lymphoproliferative
 conditions, and graft versus host disease. Based on its immunosuppressive properties, we treated 14 AA patients with alemtuzumab.
 Median age was 23&amp;nbsp;years. Ten milligrams of alemtuzumab were injected subcutaneously each day for five consecutive days. Cyclosporine
 A was also administered orally at a dose of 2&amp;nbsp;mg/kg every 12&amp;nbsp;h for 3&amp;nbsp;months, and then gradually tapered. Response to alemtuzumab
 was followed for a median of 20&amp;nbsp;months. There were eight responses (57.1%), two complete and six part...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2731975</comments>
            <pubDate>Mon, 24 Aug 2009 16:51:32 +0100</pubDate>
            <guid isPermaLink="false">2731975</guid>        </item>
        <item>
            <title>Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART</title>
            <link>http://www.medworm.com/index.php?rid=2731977&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft7636666k86j3613%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0815-6Authors
		Sabine Blum, Centre Hospitalier Universitaire Vaudois Service of Haematology Rue du Bugnon 46 1011 Lausanne SwitzerlandMatthias Cavassini, Centre Hospitalier Universitaire Vaudois Department of Infectious Diseases Rue du Bugnon 46 1011 Lausanne SwitzerlandJean-François Lambert, Centre Hospitalier Universitaire Vaudois Service of Haematology Rue du Bugnon 46 1011 Lausanne SwitzerlandAurélie Fayet, Centre Hospitalier Universitaire Vaudois Division of Clinical Pharmacology Rue du Bugnon 46 1011 Lausanne SwitzerlandMarc Schapira, Centre Hospitalier Universitaire Vaudois Service of Haematology Rue du Bugnon 46 1011 Lausanne SwitzerlandMartine Jotterand, Centre Hospitalier Universitaire Vaudois Un...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2731977</comments>
            <pubDate>Mon, 24 Aug 2009 16:51:31 +0100</pubDate>
            <guid isPermaLink="false">2731977</guid>        </item>
        <item>
            <title>Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients</title>
            <link>http://www.medworm.com/index.php?rid=2723695&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F30g414932781934t%2F</link>
            <description>In conclusion, rituximab-based therapy may cause serious HBV-related complications and even death
 in both HBsAg-positive and HBsAg-negative patients.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0806-7Authors
		Sung-Nan Pei, Chang Gung University College of Medicine Division of Hema-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital–Kaohsiung Medical Center Kaohsiung TaiwanChien-Hung Chen, Chang Gung University College of Medicine Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital–Kaohsiung Medical Center Kaohsiung TaiwanChuan-Mo Lee, Chang Gung University College of Medicine Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital–Kaohsiung ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2723695</comments>
            <pubDate>Fri, 21 Aug 2009 15:26:45 +0100</pubDate>
            <guid isPermaLink="false">2723695</guid>        </item>
        <item>
            <title>A novel t(1;12)(q21;q24) in a patient with myelodysplastic syndrome</title>
            <link>http://www.medworm.com/index.php?rid=2723694&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb168k37405034262%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0814-7Authors
		Tae Sung Park, Kyung Hee University School of Medicine Department of Laboratory Medicine 1 Hoegi-dong, Dongdaemun-gu Seoul 130-702 KoreaSang-Guk Lee, Yonsei University College of Medicine Department of Laboratory Medicine 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaJaewoo Song, Yonsei University College of Medicine Department of Laboratory Medicine 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaJin Seok Kim, Yonsei University College of Medicine Department of Internal Medicine 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaJong Rak Choi, Yonsei University College of Medicine Department of Laboratory Medicine 250 Seongsanno, Seodaemun-gu Seoul 120-752 Korea
	

	
		Journal Annals of Hemato...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2723694</comments>
            <pubDate>Fri, 21 Aug 2009 15:26:45 +0100</pubDate>
            <guid isPermaLink="false">2723694</guid>        </item>
        <item>
            <title>Sheehan’s syndrome with pancytopenia—complete recovery after hormone replacement (case series with review)</title>
            <link>http://www.medworm.com/index.php?rid=2723696&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa7167585x74q3532%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Reports of pancytopenia in patients with Sheehan’s syndrome are rare, because the disorder is not commonly seen in western
 countries. A case series of pancytopenia in three patients of Sheehan’s syndrome is presented. Three women aged 22, 30, and
 34&amp;nbsp;years developed Sheehan’s syndrome preceded by post partum hemorrhage. During investigations, they were found to have pancytopenia
 with hypocellular marrow. Treatment with thyroxine and glucocorticoids resulted in complete recovery after attaining euthyroid
 and eucortisolemic state. Review of literature revealed the rarity of the disorder, with only four cases reported so far.
 Multiple anterior pituitary hormone deficiencies in Sheehan’s syndrome are responsible for pancytopenia; replacement of thyroid
 and...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2723696</comments>
            <pubDate>Fri, 21 Aug 2009 15:26:43 +0100</pubDate>
            <guid isPermaLink="false">2723696</guid>        </item>
        <item>
            <title>Peripheral blood stem cell collection in elderly patients</title>
            <link>http://www.medworm.com/index.php?rid=2721754&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx2030h0g23344rt4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Intensive treatments like autologous blood stem cell transplantations are standard consolidation treatments for lymphoma and
 myeloma in young people. The upper age limit for these procedures is constantly increasing. Instead of studying the impact
 of aging on harvesting peripheral blood stem cells (PBSC), we performed a retrospective study to explore the feasibility of
 collecting stem cells from patients older than 65&amp;nbsp;years and compared the efficacy to harvest in younger patients. During a
 period of 7&amp;nbsp;years, we identified 108 patients with myeloma or lymphoma who were older than 65&amp;nbsp;years who underwent PBSC collection.
 Only eight patients failed to produce a successful harvest. The majority of patients only needed one apheresis (71%). There
 was a med...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2721754</comments>
            <pubDate>Thu, 20 Aug 2009 08:29:14 +0100</pubDate>
            <guid isPermaLink="false">2721754</guid>        </item>
        <item>
            <title>Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report</title>
            <link>http://www.medworm.com/index.php?rid=2721755&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F67rh5k1550277krx%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0810-yAuthors
		Wan Kyu Eo, Kyung Hee University, East-West Neo Medical Center Integrative Cancer Center Seoul South KoreaSe Hyun Kim, Kyung Hee University Graduate School of East-West Medical Science Yongin South KoreaSeong Ha Cheon, Kyung Hee University, East-West Neo Medical Center Integrative Cancer Center Seoul South KoreaSang Hun Lee, Kyung Hee University, East-West Neo Medical Center Integrative Cancer Center Seoul South KoreaJong Soo Jeong, Kyung Hee University, East-West Neo Medical Center Integrative Cancer Center Seoul South KoreaYang Soo Kim, Kosin University College of Medicine Department of Internal Medicine Busan South KoreaHee Kyung Chang, Kosin University College of Medicine Department of Pat...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2721755</comments>
            <pubDate>Thu, 20 Aug 2009 08:29:13 +0100</pubDate>
            <guid isPermaLink="false">2721755</guid>        </item>
        <item>
            <title>Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2721756&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm52k857u64t15078%2F</link>
            <description>This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated
 aggressive lymphoma. One hundred and fifteen patients with untreated aggressive lymphoma were stratified by center, age, and
 international prognostic index and randomized to one of two treatment arms. One hundred and three were eligible. The experimental
 dose-dense arm consisted of weekly therapy with cyclophosphamide, epirubicine, vincristine, prednisolone, ifosfamide, etoposide,
 methotrexate, dexamethasone, and filgrastim (CEOP/IMVP-Dexa). The standard arm consisted of three-weekly cyclophosphamide,
 doxorubicin, vincristine, and prednisolone (CHOP). The primary endpoint was overall survival after 3&amp;nbsp;years. Overall survival
 at 3&amp;nbsp;years was 0.766 (95% CI 0...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2721756</comments>
            <pubDate>Thu, 20 Aug 2009 08:29:11 +0100</pubDate>
            <guid isPermaLink="false">2721756</guid>        </item>
        <item>
            <title>Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2717803&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft63471185n506058%2F</link>
            <description>We describe our experience with the administration
 of rituximab post-ASCT, either as maintenance therapy or for the treatment of relapsed disease in patients with aggressive
 B cell NHL. Fifty-six patients achieved complete remission post-transplant, and 19 of them received maintenance with rituximab.
 Maintenance with rituximab resulted in statistically significant superior outcome in terms of progression free (PFS; p = 0.002) and overall survival (OS; p = 0.011). The median PFS and OS of patients in the maintenance arm has not been reached yet, while the median PFS and OS
 of patients in the control arm were 29 and 42&amp;nbsp;months, respectively. Fifty-four patients had disease progression or relapsed
 post-ASCT, and 15 of them received rituximab in combination with chemo- and/or ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2717803</comments>
            <pubDate>Wed, 19 Aug 2009 18:01:53 +0100</pubDate>
            <guid isPermaLink="false">2717803</guid>        </item>
        <item>
            <title>Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years</title>
            <link>http://www.medworm.com/index.php?rid=2717804&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa774532n272r3jq6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated
 with extremely poor survival. In addition, its treatment included high-dose dexamethasone and/or thalidomide-containing regimens
 on the reversibility of renal function, which has not been adequately evaluated previously. We studied the impact on the reversibility
 of high-dose dexamethasone and/or thalidomide-containing regimen in 12 newly diagnosed MM patients (median 74&amp;nbsp;years, range;
 63–85&amp;nbsp;years) who required dialysis at Kameda General Hospital from 2001 to 2008. There were seven light chain only myelomas,
 three IgD myelomas, and two IgG myelomas. Ten patients initially received high-dose dexamethasone-based treatment and two
 recei...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2717804</comments>
            <pubDate>Wed, 19 Aug 2009 18:01:49 +0100</pubDate>
            <guid isPermaLink="false">2717804</guid>        </item>
        <item>
            <title>Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements</title>
            <link>http://www.medworm.com/index.php?rid=2717805&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff545m44565665657%2F</link>
            <description>In conclusion, most low-risk transfusion-dependent MDS
 patients develop IO, but only a minority receives a minimally effective and timely iron chelation therapy.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0794-7Authors
		Angel F. Remacha, Centro Hospitalario de Toledo Hematology Department Avenida Barber, 30. 45004 Toledo SpainBeatriz Arrizabalaga, Hospital de Cruces Barakaldo SpainConsuelo Del Cañizo, Hospital Universitario de Salamanca Salamanca SpainGuillermo Sanz, Hospital La Fe Valencia SpainAna Villegas, Hospital Clínico San Carlos Madrid Spain
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2717805</comments>
            <pubDate>Wed, 19 Aug 2009 08:26:21 +0100</pubDate>
            <guid isPermaLink="false">2717805</guid>        </item>
        <item>
            <title>Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2714077&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F94k2530v401h2vk3%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0809-4Authors
		Sung-Hsin Kuo, National Taiwan University Hospital and National Taiwan University College of Medicine Department of Oncology Taipei TaiwanRuoh-Fang Yen, National Taiwan University Hospital and National Taiwan University College of Medicine Department of Nuclear Medicine Taipei TaiwanChung-Wu Lin, National Taiwan University Hospital and National Taiwan University College of Medicine Department of Pathology Taipei TaiwanLi-Tzong Chen, National Health Research Institutes Institute of Cancer Research Taipei TaiwanHwei-Fang Tien, National Taiwan University Hospital and National Taiwan University College of Medicine Department of Internal Medicine Taipei TaiwanAnn-Lii Cheng, National Taiwan Universi...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2714077</comments>
            <pubDate>Mon, 17 Aug 2009 19:07:21 +0100</pubDate>
            <guid isPermaLink="false">2714077</guid>        </item>
        <item>
            <title>Treatment of multiple myeloma and arterial thrombosis</title>
            <link>http://www.medworm.com/index.php?rid=2714078&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq23q67n121061611%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0803-xAuthors
		Wouter Raven, Maasstad Hospital Department of Internal Medicine Rotterdam The NetherlandsArie Berghout, Maasstad Hospital Department of Internal Medicine Rotterdam The NetherlandsAnja van Houten, Maasstad Hospital Department of Internal Medicine Rotterdam The NetherlandsFrank W. G. Leebeek, Erasmus University Medical Center Department of Hematology Rotterdam The Netherlands
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2714078</comments>
            <pubDate>Mon, 17 Aug 2009 19:07:19 +0100</pubDate>
            <guid isPermaLink="false">2714078</guid>        </item>
        <item>
            <title>A rare case of extranasal NK/T cell lymphoma presenting as autoimmune rheumatic manifestations associated with Sjögren's syndrome</title>
            <link>http://www.medworm.com/index.php?rid=2710531&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F852v42154n044248%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0805-8Authors
		Bing Yan, West China Hospital of Sichuan University Department of Rheumatology No. 37, Guoxue Alley Chengdu Sichuan Province 610041 ChinaYi Liu, West China Hospital of Sichuan University Department of Rheumatology No. 37, Guoxue Alley Chengdu Sichuan Province 610041 ChinaDan Hu, West China Hospital of Sichuan University Department of Rheumatology No. 37, Guoxue Alley Chengdu Sichuan Province 610041 ChinaGandi Li, West China Hospital of Sichuan University Department of Pathology Chengdu Sichuan Province 610041 China
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2710531</comments>
            <pubDate>Sun, 16 Aug 2009 19:23:26 +0100</pubDate>
            <guid isPermaLink="false">2710531</guid>        </item>
        <item>
            <title>Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis</title>
            <link>http://www.medworm.com/index.php?rid=2697533&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxk372808wl5j0738%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0802-yAuthors
		Wan-Ling Sun, Xuanwu Hospital Capital Medical University Department of Hematology Beijing ChinaLeonhard Köck, County Hospital of Lienz Department of Internal Medicine Lienz AustriaAlois Walder, County Hospital of Lienz Department of Internal Medicine Lienz AustriaMartin Erdel, Medical University of Innsbruck Department of Human Genetics/Cytogenetics Innsbruck AustriaSusanne Kilga-Nogler, Central Hospital of Innsbruck Institute of Transfusion Medicine Innsbruck AustriaHarald Schennach, Central Hospital of Innsbruck Institute of Transfusion Medicine Innsbruck AustriaMichael Fiegl, Medical University of Innsbruck Department of Internal Medicine V, Division of Hematology and Oncology Anichstrasse...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2697533</comments>
            <pubDate>Tue, 11 Aug 2009 16:53:53 +0100</pubDate>
            <guid isPermaLink="false">2697533</guid>        </item>
        <item>
            <title>The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment</title>
            <link>http://www.medworm.com/index.php?rid=2697534&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F249l628651242528%2F</link>
            <description>The objective of this study was to evaluate the prognostic value of immunohistochemical
 subtyping and the International Prognostic Index (IPI) for predicting treatment outcome in Chinese DLBCL patients. We followed
 108 cases of DLBCL and performed prognostic analyses based on molecular subtyping of the disease through immunostaining of
 tissue samples. The use of rituximab conferred a clinical benefit to DLBCL patients regardless of disease subtype. Importantly,
 this treatment regimen also improved outcomes in patients with the non-germinal centre B-cell-like (GCB) DLBCL subtype, frequently
 associated with poorer prognosis. Our results suggest that IPI was the best tool for the prediction of treatment outcome in
 our patient cohort, regardless of treatment regimen. Furthermore, the use...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2697534</comments>
            <pubDate>Tue, 11 Aug 2009 00:00:30 +0100</pubDate>
            <guid isPermaLink="false">2697534</guid>        </item>
        <item>
            <title>A novel β-globin gene deletion (codons 89–93) in a Chinese family</title>
            <link>http://www.medworm.com/index.php?rid=2680030&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F32g585g10815q61r%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0798-3Authors
		Dong-Zhi Li, Guangzhou Maternal and Neonatal Hospital Prenatal Diagnostic Center Renminzhong Road 402 Guangzhou Guangdong 510180 ChinaCan Liao, Guangzhou Maternal and Neonatal Hospital Prenatal Diagnostic Center Renminzhong Road 402 Guangzhou Guangdong 510180 ChinaJian Li, Guangzhou Maternal and Neonatal Hospital Prenatal Diagnostic Center Renminzhong Road 402 Guangzhou Guangdong 510180 ChinaRu Li, Guangzhou Maternal and Neonatal Hospital Prenatal Diagnostic Center Renminzhong Road 402 Guangzhou Guangdong 510180 China
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2680030</comments>
            <pubDate>Tue, 04 Aug 2009 21:15:47 +0100</pubDate>
            <guid isPermaLink="false">2680030</guid>        </item>
        <item>
            <title>Long-term response to deferiprone therapy in Asian Indians</title>
            <link>http://www.medworm.com/index.php?rid=2680031&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F352753623v04j153%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Deferiprone (L1) has been used in several countries for iron chelation therapy for over one decade. Long-term results on the
 drug are lacking. In the present study, data of 110 patients on deferiprone (L1) for up to 17&amp;nbsp;years were analyzed. On a mean
 L1 dose of 70.2&amp;nbsp;mg/kg/day (range 44–100), serum ferritin level showed a very steady decrease with time from an initial mean
 (±SD) of 3,033.61 ± 1,468.04&amp;nbsp;ng/ml to final of 1,665.08 ± 949.93&amp;nbsp;ng/ml after a mean (±SD) of 6.1 ± 3.8&amp;nbsp;years. In total, 13
 patients discontinued L1 therapy. Major complications of L1 requiring permanent discontinuation of treatment included arthropathy
 (n = 8, 7.2%) and neutropenia/agranulocytosis (n = 5, 4.5%). Lesser complications permitting con...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2680031</comments>
            <pubDate>Tue, 04 Aug 2009 21:15:46 +0100</pubDate>
            <guid isPermaLink="false">2680031</guid>        </item>
        <item>
            <title>Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura</title>
            <link>http://www.medworm.com/index.php?rid=2661629&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F52w63t307749k37q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To investigate the role of Notch signaling pathway in immune thrombocytopenic purpura (ITP), we measured the expression of
 11 Notch pathway molecules in ITP patients and evaluated their clinical relevance. Real-time reverse transcriptase polymerase
 chain reaction results showed there was aberrant expression of some Notch molecules in ITP. Notch1 and Notch3 expression elevated,
 while Notch2 decreased statistically in ITP patients. As for Notch ligands, only DLL1 was found downregulated in ITP. The
 expression of Notch target gene, Hes1, was also upregulated. In accordance with the mRNA level, Notch1 and Hes1 protein expression
 was also found elevated by Western blot. Immunocytochemistry showed that Notch1 expressed highly in the cytomembrane, cytoplasm,
 and part of ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2661629</comments>
            <pubDate>Thu, 30 Jul 2009 19:53:18 +0100</pubDate>
            <guid isPermaLink="false">2661629</guid>        </item>
        <item>
            <title>Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant)</title>
            <link>http://www.medworm.com/index.php?rid=2651670&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fwm418q416576041v%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0795-6Authors
		Marta Anna Sobas, Hospital Clinico Universitario de Santiago de Compostela Servicio de Hematologia y Hemoterapia c/Choupana s/n 15-706 Santiago de Compostela SpainNatalia Alonso Vence, Hospital Clinico Universitario de Santiago de Compostela Servicio de Hematologia y Hemoterapia c/Choupana s/n 15-706 Santiago de Compostela SpainJose Diaz Arias, Hospital Clinico Universitario de Santiago de Compostela Servicio de Hematologia y Hemoterapia c/Choupana s/n 15-706 Santiago de Compostela SpainAngeles Bendaña Lopez, Hospital Clinico Universitario de Santiago de Compostela Servicio de Hematologia y Hemoterapia c/Choupana s/n 15-706 Santiago de Compostela SpainMaximo Fraga Rodriguez, Hospital Clinico ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2651670</comments>
            <pubDate>Mon, 27 Jul 2009 21:44:06 +0100</pubDate>
            <guid isPermaLink="false">2651670</guid>        </item>
        <item>
            <title>Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age</title>
            <link>http://www.medworm.com/index.php?rid=2651671&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm851226x71q8314j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We used nonpegylated liposomal doxorubicin (NPLD) in cytostatic drug combinations to treat 37 patients with non-Hodgkin's
 lymphoma and pre-existing cardiac disorder or elderly patients with reduced physical state who were ineligible for conventional
 anthracycline-containing therapy. High remission rates were observed in this poor-risk population: Complete remission rates
 were 75% for diffuse large B cell lymphoma (DLBCL) and 55% for T/NK cell neoplasm (overall response rate of 80% and 89%, respectively).
 Twenty-seven patients (73%) are still alive after a median observation time of 14&amp;nbsp;months. No major cardiac or gastrointestinal
 toxicity was observed. Extravasation of NPLD in two patients resulted in mild inflammation without tissue damage. Hematologic
 toxici...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2651671</comments>
            <pubDate>Mon, 27 Jul 2009 21:44:01 +0100</pubDate>
            <guid isPermaLink="false">2651671</guid>        </item>
        <item>
            <title>Occult Hodgkin lymphoma presenting as polymyalgia rheumatica: value of [(18)F]-FDG positron emission tomography</title>
            <link>http://www.medworm.com/index.php?rid=2642920&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa2635g0g31767161%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0779-6Authors
		C. Durant, CHU Hotel Dieu Service de Médecine Interne 1, place Alexis Ricordeau 44093 Nantes Cedex FranceB. Hervier, CHU Hotel Dieu Service de Médecine Interne 1, place Alexis Ricordeau 44093 Nantes Cedex FranceC. Ansquer, CHU Hotel Dieu Nuclear Medicine Nantes FranceA. Masseau, CHU Hotel Dieu Service de Médecine Interne 1, place Alexis Ricordeau 44093 Nantes Cedex FranceM. Hamidou, CHU Hotel Dieu Service de Médecine Interne 1, place Alexis Ricordeau 44093 Nantes Cedex France
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2642920</comments>
            <pubDate>Sat, 25 Jul 2009 14:46:10 +0100</pubDate>
            <guid isPermaLink="false">2642920</guid>        </item>
        <item>
            <title>A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=2642921&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqx75172vv107373j%2F</link>
            <description>In conclusion, when given at a dose of 100&amp;nbsp;mg twice daily alone or combined with dexamethasone,
 ITF2357 proved tolerable but showed a modest clinical benefit in advanced MM.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0793-8Authors
		Monica Galli, Ospedali Riuniti Div. of Hematology Largo Barozzi, 1 24128 Bergamo ItalySilvia Salmoiraghi, Ospedali Riuniti Div. of Hematology Largo Barozzi, 1 24128 Bergamo ItalyJoseé Golay, Ospedali Riuniti Div. of Hematology Largo Barozzi, 1 24128 Bergamo ItalyAntonella Gozzini, Azienda Ospedaliera Universitaria Careggi Firenze ItalyClaudia Crippa, Spedali Civili Div. of Hematology Brescia ItalyNorbert Pescosta, Ospedale S. Maurizio Div. of Hematology Bolzano ItalyAlessandro Rambaldi, Ospedali Riuniti Div. of Hematol...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2642921</comments>
            <pubDate>Sat, 25 Jul 2009 14:46:06 +0100</pubDate>
            <guid isPermaLink="false">2642921</guid>        </item>
        <item>
            <title>The use of desmopressin in congenital factor XI deficiency: a systematic review</title>
            <link>http://www.medworm.com/index.php?rid=2623466&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F256l3705g7231610%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Factor XI (FXI) deficiency is a rare inherited coagulation disorder characterized by infrequent spontaneous bleeding, but
 increased risk of hemorrhagic complications especially after trauma or surgery. Treatment options for FXI-deficient patients
 include virus-inactivated fresh frozen plasma, plasma-derived FXI concentrates, and activated recombinant FVII. Inhibitors
 of fibrinolysis, such as tranexamic acid, and desmopressin (DDAVP) have also been used in these patients, especially in mild
 cases. The current knowledge on the use of the latter agent in this congenital bleeding condition is systematically reviewed
 here. Although limited, the available literature data suggest the potential role of DDAVP for either treatment of bleeding
 episodes or the prevention of p...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2623466</comments>
            <pubDate>Sat, 18 Jul 2009 21:47:07 +0100</pubDate>
            <guid isPermaLink="false">2623466</guid>        </item>
        <item>
            <title>Wrong molar hemoglobin reference values—a longstanding error that should be corrected</title>
            <link>http://www.medworm.com/index.php?rid=2623467&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr5047542152u4336%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0791-xAuthors
		Peter Lodemann, Blood Transfusion Service Zuerich SRK Ruetistr. 19 8952 Schlieren SwitzerlandGeorg Schorer, Blood Transfusion Service Zuerich SRK Ruetistr. 19 8952 Schlieren SwitzerlandBeat M. Frey, Blood Transfusion Service Zuerich SRK Ruetistr. 19 8952 Schlieren Switzerland
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2623467</comments>
            <pubDate>Sat, 18 Jul 2009 21:47:03 +0100</pubDate>
            <guid isPermaLink="false">2623467</guid>        </item>
        <item>
            <title>HbA2-Partinico or δ(A2)Pro→Thr, a new genetic variation in the δ-globin gene in cis to the β+ thal IVS-I-110 G&gt;A, and the heterogeneity of δ-globin alleles in double heterozygotes for β- and δ-globin gene defects</title>
            <link>http://www.medworm.com/index.php?rid=2623468&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh5p611r223556226%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The study of the alleles of the δ-globin gene is relevant to the prevention of β-thalassemia homozygosis; in fact, the increase
 of the HbA2 is an invaluable hematological marker of the β-thalassemia heterozygosis and the double heterozygosis for alleles
 of δ- and β-globin genes can cause the decrease of the HbA2 up to normal or borderline values. We carried out the characterization
 of alleles of the δ- and β-globin genes, restriction fragment length polymorphism (RFLP) haplotype background, and hematologic
 phenotype in 23 double heterozygotes belonging to 18 unrelated families. A wide heterogeneity of the δ-globin alleles was
 detected; seven known alleles in trans to the β-globin gene defects were revealed in 17 out of 18 families, while a new allele in ci...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2623468</comments>
            <pubDate>Sat, 18 Jul 2009 21:47:02 +0100</pubDate>
            <guid isPermaLink="false">2623468</guid>        </item>
        <item>
            <title>Cutaneous myeloma and bortezomib</title>
            <link>http://www.medworm.com/index.php?rid=2603919&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3526478818711305%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0786-7Authors
		Alessandro Gozzetti, Policlinico “Santa Maria alle Scotte” Division of Hematology and Transplants Viale Bracci 16 53100 Siena ItalyMarzia Defina, Policlinico “Santa Maria alle Scotte” Division of Hematology and Transplants Viale Bracci 16 53100 Siena ItalyMonica Bocchia, Policlinico “Santa Maria alle Scotte” Division of Hematology and Transplants Viale Bracci 16 53100 Siena Italy
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2603919</comments>
            <pubDate>Tue, 14 Jul 2009 09:56:13 +0100</pubDate>
            <guid isPermaLink="false">2603919</guid>        </item>
        <item>
            <title>Therapy of hepatitis C in thalassemia: the influence of iron on achieving sustained viral response</title>
            <link>http://www.medworm.com/index.php?rid=2592411&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0235148661143654%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0785-8Authors
		Seyed-Moayed Alavian, Baqiyatallah University of Medical Sciences Research Center for Gastroenterology and Liver Disease Tehran IranSeyed-Vahid Tabatabaei, Baqiyatallah University of Medical Sciences Research Center for Gastroenterology and Liver Disease Tehran Iran
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592411</comments>
            <pubDate>Fri, 10 Jul 2009 08:09:10 +0100</pubDate>
            <guid isPermaLink="false">2592411</guid>        </item>
        <item>
            <title>Abdominal pain in a patient with acute lymphoblastic leukaemia</title>
            <link>http://www.medworm.com/index.php?rid=2592412&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg896223434856555%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0789-4Authors
		Alexander Breitenstein, University Hospital Zurich Department of Internal Medicine Rämistrasse 100 8091 Zurich SwitzerlandReto Kühne, University Hospital Zurich Hematology Department Zurich SwitzerlandElisabeth I. Minder, Stadtspital Triemli Zentrallabor Zurich SwitzerlandAleksandra Marek, University Hospital Zurich Hematology Department Zurich SwitzerlandJeroen Goede, University Hospital Zurich Hematology Department Zurich SwitzerlandUrs Schanz, University Hospital Zurich Hematology Department Zurich SwitzerlandChristoph Renner, University Hospital Zurich Hematology Department Zurich Switzerland
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of ...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592412</comments>
            <pubDate>Thu, 09 Jul 2009 12:37:13 +0100</pubDate>
            <guid isPermaLink="false">2592412</guid>        </item>
        <item>
            <title>A case of generalized MALT lymphoma with IgM paraproteinemia and peripheral blood involvement</title>
            <link>http://www.medworm.com/index.php?rid=2589884&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fpj815j86661r49k5%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0787-6Authors
		Sonja Reitter, Medical University Graz Division of Hematology Auenbruggerplatz 38 8036 Graz AustriaPeter Neumeister, Medical University Graz Division of Hematology Auenbruggerplatz 38 8036 Graz AustriaChristine Beham-Schmid, Medical University Graz Institute of Pathology Auenbruggerplatz 25 8036 Graz AustriaWerner Emberger, Medical University Graz Institute of Human Genetics Harrachgasse 21/8 8010 Graz AustriaDirk Strunk, Medical University Graz Division of Hematology Auenbruggerplatz 38 8036 Graz AustriaRuth Brezinschek, Medical University Graz Division of Hematology Auenbruggerplatz 38 8036 Graz AustriaWerner Linkesch, Medical University Graz Division of Hematology Auenbruggerplatz 38 8036 G...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2589884</comments>
            <pubDate>Tue, 07 Jul 2009 15:24:03 +0100</pubDate>
            <guid isPermaLink="false">2589884</guid>        </item>
        <item>
            <title>Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2589883&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp473226658g72786%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0783-xAuthors
		Masataka Hosoi, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 JapanGo Yamamoto, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 JapanYoichi Imai, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 JapanMineo Kurokawa, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 Japan
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2589883</comments>
            <pubDate>Tue, 07 Jul 2009 15:24:03 +0100</pubDate>
            <guid isPermaLink="false">2589883</guid>        </item>
        <item>
            <title>Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation</title>
            <link>http://www.medworm.com/index.php?rid=2589882&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F86t374361742888p%2F</link>
            <description>In conclusion, a homozygous JAK2 V617F mutation is an independent risk factor for recurrent thrombosis
 in patients with ET.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0788-5Authors
		Valerio De Stefano, Catholic University Institute of Hematology Largo Gemelli 8 00168 Rome ItalyTommaso Za, Catholic University Institute of Hematology Largo Gemelli 8 00168 Rome ItalyElena Rossi, Catholic University Institute of Hematology Largo Gemelli 8 00168 Rome ItalyAlessandro M. Vannucchi, University of Florence The Department of Hematology Florence ItalyMarco Ruggeri, San Bortolo Hospital The Hematology Department and Hemophilia and Thrombosis Center Vicenza ItalyElena Elli, University of Milano-Bicocca The Hematology Division and Bone Marrow Transplantation Unit, S...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2589882</comments>
            <pubDate>Tue, 07 Jul 2009 15:24:03 +0100</pubDate>
            <guid isPermaLink="false">2589882</guid>        </item>
        <item>
            <title>Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival</title>
            <link>http://www.medworm.com/index.php?rid=2589885&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff8556603p2345553%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The prognosis of follicular lymphoma could vary with the tumor immune microenvironment. We evaluated the prognostic value
 of serum levels of ten cytokines. Our study cohort included 60 follicular lymphoma patients and 20 controls. Serum was available
 at diagnosis in 31 patients, at first relapse in 18, and complete remission in 11. Bioplex technology was used for determination
 of nine cytokines [interleukin (IL)-1Ra, IL-6, IL-7, IL-10, IL-13, tumor necrosis factor alpha (TNF-α), vascular endothelial
 growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (b-FGF)]. Transforming growth
 factor beta (TGF-β) was measured by sandwich enzyme-linked immunosorbent assay. IL-1Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF,
 and PDGF leve...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2589885</comments>
            <pubDate>Tue, 07 Jul 2009 15:24:02 +0100</pubDate>
            <guid isPermaLink="false">2589885</guid>        </item>
        <item>
            <title>Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells</title>
            <link>http://www.medworm.com/index.php?rid=2589887&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm022qn3658685618%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The cytolytic activity of cells expressing natural killer cell receptors (NKRs) depends on the balance between stimulatory
 and inhibitory signals. We investigated both inhibitory NK receptor (CD94/NKG2A) expression and stimulatory NKR (NKG2D) expression
 on T cells after stimulation with cytokines (IL-12 or IL-15). Cytolytic NKR-expressing CD8+ T cells were expanded from normal adult peripheral blood mononuclear cells using anti-CD3 monoclonal antibody and cytokines
 (IL-12 or IL-15). The proportion and absolute number of CD94/NKG2A-expressing T cells expanded by IL-12 were significantly
 larger than those of the cells expanded by IL-15. On the other hand, the proportion and absolute number of NKG2D-expressing
 T cells expanded by IL-15 were significantly larger than t...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2589887</comments>
            <pubDate>Mon, 06 Jul 2009 20:14:44 +0100</pubDate>
            <guid isPermaLink="false">2589887</guid>        </item>
        <item>
            <title>Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2589886&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fwp57420n55n5t237%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0782-yAuthors
		Claudio Fozza, University of Sassari Institute of Haematology Viale San Pietro 12 07100 Sassari ItalyAntonio Galleu, University of Sassari Institute of Haematology Viale San Pietro 12 07100 Sassari ItalyMaria Grazia Careddu, University of Sassari Institute of Haematology Viale San Pietro 12 07100 Sassari ItalyDomenica Barbara Giannico, University of Sassari Institute of Haematology Viale San Pietro 12 07100 Sassari ItalySilvana Bonfigli, University of Sassari Institute of Haematology Viale San Pietro 12 07100 Sassari ItalySalvatore Contini, University of Sassari Institute of Haematology Viale San Pietro 12 07100 Sassari ItalyMaurizio Longinotti, University of Sassari Institute of Haematology V...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2589886</comments>
            <pubDate>Mon, 06 Jul 2009 20:14:44 +0100</pubDate>
            <guid isPermaLink="false">2589886</guid>        </item>
        <item>
            <title>Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia</title>
            <link>http://www.medworm.com/index.php?rid=2578297&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnu4m5m7x30263w80%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0781-zAuthors
		Kalina Ramadanova, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology Department of Internal Medicine I Fetscherstr. 74 01307 Dresden GermanyHansjörg Hoff, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology Department of Neuroradiology Fetscherstr. 74 01307 Dresden GermanyNicola Gökbuget, University Hospital Johann-Wolfgang Goethe Department of Internal Medicine II Theodor-Stern Kai 7 60590 Frankfurt/Main GermanyUlrike Reuner, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology Department of Neurology Fetscherstr. 74 01307 Dresden GermanySusanne Hamann, University Hospital Carl Gustav Carus Dresden, Dresden...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2578297</comments>
            <pubDate>Mon, 06 Jul 2009 16:50:11 +0100</pubDate>
            <guid isPermaLink="false">2578297</guid>        </item>
        <item>
            <title>A case report of non-traumatic renal artery pseudoaneurysm due to chemotherapy for diffuse large B-cell lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2578298&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw84150703l763814%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0776-9Authors
		Yosuke Masamoto, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 JapanYoichi Imai, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 JapanSachiko Seo, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 JapanMasaaki Akahane, University of Tokyo Department of Radiology, Graduate School of Medicine Tokyo JapanMineo Kurokawa, University of Tokyo Department of Hematology &amp; Oncology, Graduate School of Medicine 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 Japan
	

	
		Journal Annals of Hema...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2578298</comments>
            <pubDate>Mon, 06 Jul 2009 16:50:10 +0100</pubDate>
            <guid isPermaLink="false">2578298</guid>        </item>
        <item>
            <title>Thrombocytopenia as first manifestation of splenic angiosarcoma</title>
            <link>http://www.medworm.com/index.php?rid=2565099&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr3q00x268gn26412%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0778-7Authors
		Simon Raffel, Charité Campus Virchow Klinikum Department of Hematology and Oncology Augustenburger Platz 1 13353 Berlin GermanyBert Hildebrandt, Charité Campus Virchow Klinikum Department of Hematology and Oncology Augustenburger Platz 1 13353 Berlin GermanyChristian Grieser, Charité Campus Virchow Klinikum Department of Radiology Augustenburger Platz 1 13353 Berlin GermanyStefan Pahl, Charité Campus Mitte Institute of Pathology Charitéplatz 1 10117 Berlin GermanyIsrid Sturm, Charité Campus Virchow Klinikum Department of Hematology and Oncology Augustenburger Platz 1 13353 Berlin Germany
	

	
		Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hemat...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2565099</comments>
            <pubDate>Wed, 01 Jul 2009 06:13:18 +0100</pubDate>
            <guid isPermaLink="false">2565099</guid>        </item>
        <item>
            <title>Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin</title>
            <link>http://www.medworm.com/index.php?rid=2565100&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy727411813210568%2F</link>
            <description>This study identifies pretreatment parameters that may
 help identify high-risk patients who are more likely to develop hematological abnormalities during treatment for chronic hepatitis
 C.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0774-yAuthors
		Jagdish S. Nachnani, University of Missouri Kansas City School of Medicine Division of Gastroenterology 2301 Holmes Street Kansas City MO 64108 USAGowtham A. Rao, VA Medical Center Kansas City Division of Gastroenterology Kansas City MO 64108 USADeepti Bulchandani, VA Medical Center Kansas City Division of Gastroenterology Kansas City MO 64108 USAPrashant K. Pandya, VA Medical Center Kansas City Division of Gastroenterology Kansas City MO 64108 USALaura M. Alba, University of Missouri Kansas City School of Me...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2565100</comments>
            <pubDate>Tue, 30 Jun 2009 15:40:17 +0100</pubDate>
            <guid isPermaLink="false">2565100</guid>        </item>
        <item>
            <title>Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?</title>
            <link>http://www.medworm.com/index.php?rid=2557994&amp;cid=s_33273_19_f&amp;fid=33273&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft7700283t0w040g7%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0775-xAuthors
		Donat Dürr, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandRaffaele Daniele Siciliano, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandYvonne Hummel, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandAlix O’Meara, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandAnita Hirschi, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandRoger Burkhard, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandHanspeter Honegger, Stadtspital Triemli Medical Oncology Birmensdorfers...</description>
            <author>Annals of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2557994</comments>
            <pubDate>Mon, 29 Jun 2009 09:59:28 +0100</pubDate>
            <guid isPermaLink="false">2557994</guid>        </item>
    </channel>
</rss>
